Update S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)

Wolfgang Fischbach; Jan Bornschein; Jörg C. Hoffmann; Sibylle Koletzko; Alexander Link; Lukas Macke; Peter Malfertheiner; Kerstin Schütte; Dieter-Michael Selgrad; Sebastian Suerbaum; Christian Schulz; Collaborators

doi:10.1055/a-2181-2225

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2024; 62(02): 261-321
DOI: 10.1055/a-2181-2225

Leitlinie

Update S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)

August 2023 – AWMF-Registernummer: 021–001

Autoren

Wolfgang Fischbach

¹Gastroenterologie und Innere Medizin Aschaffenburg, Deutschland
Jan Bornschein

²Translational Gastroenterology Unit John, John Radcliffe Hospital Oxford University Hospitals, Oxford, United Kingdom
Jörg C. Hoffmann

³Medizinische Klinik I, St. Marien- und St. Annastiftskrankenhaus, Ludwigshafen, Deutschland
Sibylle Koletzko

⁴Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, LMU-Klinikum Munich, Munich, Deutschland

⁵Department of Paediatrics, Gastroenterology and Nutrition, School of Medicine Collegium Medicum University of Warmia and Mazury, 10-719 Olsztyn, Poland
Alexander Link

⁶Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinikum Magdeburg, Magdeburg, Deutschland
Lukas Macke

⁷Medizinische Klinik und Poliklinik II Campus Großhadern, Universitätsklinikum Munich, Munich, Deutschland

¹³Deutsches Zentrum für Infektionsforschung, Standort Munich, Munich, Deutschland
Peter Malfertheiner

⁶Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinikum Magdeburg, Magdeburg, Deutschland

⁷Medizinische Klinik und Poliklinik II Campus Großhadern, Universitätsklinikum Munich, Munich, Deutschland
Kerstin Schütte

⁸Klinik für Allgemeine Innere Medizin und Gastroenterologie, Niels-Stensen-Kliniken Marienhospital Osnabrück, Osnabrück, Deutschland
Dieter-Michael Selgrad

⁹Medizinische Klinik Gastroenterologie und Onkologie, Klinikum Fürstenfeldbruck, Fürstenfeldbruck, Deutschland

¹⁰Klinik für Innere Medizin 1, Universitätsklinikum Regensburg, Regensburg, Deutschland
Sebastian Suerbaum

¹¹Universität Munich, Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Munich, Deutschland

¹²Nationales Referenzzentrum Helicobacter pylori, Pettenkoferstr. 9a, 80336 Munich, Deutschland

¹³Deutsches Zentrum für Infektionsforschung, Standort Munich, Munich, Deutschland
Christian Schulz

⁷Medizinische Klinik und Poliklinik II Campus Großhadern, Universitätsklinikum Munich, Munich, Deutschland

¹³Deutsches Zentrum für Infektionsforschung, Standort Munich, Munich, Deutschland

Collaborators

Abstract

Key word

therapy - diagnostics - eradication - resistance - antibiotics

Volltext

Referenzen

References
1 Sugano KJ, Tack J, Kuipers EJ. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64 (09) 1353-1367
2 Malfertheiner P, Megraud F, O`Morain CAO. et al. Management of Helicobacter pylori infection – the MaastrichtV/Florence Consensus Report. Gut 2017; 66: 6-30
3 Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009; 374: 1449-1461
4 Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49 (03) 347-335
5 Fischbach W. Gastric mucosal-associated lymphoid tissue lymphoma. Gastroenterol Clin North Am 2013; 2 (02) 371-380
6 Huang JQ, Sridhar S, Chen Y. et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114 (06) 1169-1179
7 Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther 1999; 13 (07) 851-856
8 Eslick GD, Lim LL, Byles JE. et al. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999; 94 (09) 2373-2379
9 Xue FB, Xu YY, Wan Y. et al. Association of H. pylori infection with gastric carcinoma: a Meta analysis. World J Gastroenterol 2001; 7 (06) 801-804
10 Huang JQ, Zheng GF, Sumanac K. et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003; 125 (06) 1636-1644
11 Brenner H, Arndt V, Stegmaier C. et al. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer?. Am J Epidemiol 2004; 159 (03) 252-258
12 Siman JH, Engstrand L, Berglund G. et al. A. Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma. Scand J Gastroenterol 2007; 42 (08) 933-940
13 Parsonnet J, Hansen S, Rodriguez L. et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330 (18) 1267-1271
14 Morgner A, Lehn N, Andersen LP. et al. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000; 118 (05) 821-828
15 Solnick JV, Schauer DB. Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev 2001; 14 (01) 59-97
16 Chen Y, Segers S, Blaser MJ. Association between Helicobacter pylori and mortality in the NHANES III study. Gut 2013; 62 (09) 1262-1269
17 Erőss B, Farkas N, Vincze A. et al. Helicobacter pylori infection reduces the risk of Barrett’s esophagus: A meta-analysis and systematic review. Helicobacter 2018; 23 (04) e12504
18 Shah SC, Tepler A, Peek RM. et al. Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis-A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019; 17 (11) 2185-2198 e2183
19 Yalaki S, Pulat H, Ilhan A. Localization of Helicobacter pylori gastritis and the relation of existing histopathological features with reflux esophagitis. Scand J Gastroenterol 2020; 55 (01) 27-33
20 Usui G, Sato H, Shinozaki T. et al. Association Between Helicobacter pylori Infection and Short-segment/Long-segment Barrett’s Esophagus in a Japanese Population: A Large Cross-Sectional Study. J Clin Gastroenterol 2020; 54 (05) 439-444
21 Sugimoto M, Murata M, Mizuno H. et al. Endoscopic Reflux Esophagitis and Reflux-Related Symptoms after Helicobacter pylori Eradication Therapy: Meta-Analysis. J Clin Med 2020; 9 (09) 3007
22 Xie FJ, Zhang YP, Zheng QQ. et al. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol 2013; 19 (36) 6098-6107
23 Doorakkers E, Lagergren J, Santoni G. et al. Helicobacter pylori eradication treatment and the risk of Barrett’s esophagus and esophageal adenocarcinoma. Helicobacter 2020; 25 (03) e12688
24 Choi DS, Seo SI, Shin WG. et al. Risk for Colorectal Neoplasia in Patients With Helicobacter pylori Infection: A Systematic Review and Meta-analysis. Clin Transl Gastroenterol 2020; 11 (02) e00127
25 von Arnim U, Wex T, Link A. et al. Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis. Aliment Pharmacol Ther 2016; 43 (07) 825-830
26 Shah SC, Tepler A, Peek RM. et al. Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis-A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019; 17 (11) 2185-2198 e2183
27 Narang M, Puri AS, Sachdeva S. et al. Celiac disease and Helicobacter pylori infection in children: Is there any Association?. J Gastroenterol Hepatol 2017; 32 (06) 1178-1182
28 Bayrak NA, Tutar E, Volkan B. et al. Helicobacter pylori infection in children with celiac disease: Multi-center, cross-sectional study. Helicobacter 2020; 25 (03) e12691
29 Amlashi FI, Norouzi Z, Sohrabi A. et al. A systematic review and meta-analysis for association of Helicobacter pylori colonization and celiac disease. PLoS One 2021; 16 (03) e0241156
30 Franchini M, Cruciani M, Mengoli C. et al. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60 (02) 237-246
31 Marignani M, Angeletti S, Bordi C. et al. Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection. Scand J Gastroenterol 1997; 32 (06) 617-622
32 Suter PM, Golner BB, Goldin BR. et al. Reversal of protein-bound vitamin B12 malabsorption with antibiotics in atrophic gastritis. Gastroenterology 1991; 101 (04) 1039-1045
33 Lee AJ, Chung HH, Koh Y. et al. Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia. Sci Rep 2020; 10 (01) 9370
34 Jorgensen AR, Egeberg A, Gideonsson R. et al. Rosacea is associated with Helicobacter pylori: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2017; 31 (12) 2010-2015
35 Su J, Zhou XY, Zhang Gy. Association between Helicobacter pylori infection and migraine: a meta-analysis. World J Gastroenterol 2014; 20 (40) 14965-14972
36 Faraji F, Zarinfar N, Zanjani AT. et al. The effect of Helicobacter pylori eradication on migraine: a randomized, double blind, controlled trial. Pain Physician 2012; 15 (06) 495-498
37 Xu X, Li W, Qin L. et al. “Relationship between Helicobacter pylori infection and obesity in Chinese adults: A systematic review with meta-analysis.”. PLoS One 2019; 14 (09) e022107
38 Mansori K, Dehghanbanadaki H, Naderpour S. et al. A systematic review and meta-analysis of the prevalence of Helicobacter pylori in patients with diabetes. Diabetes Metab Syndr 2020; 14 (04) 601-607
39 Fang Y, Fan C, Xie H. Effect of Helicobacter pylori infection on the risk of acute coronary syndrome: A systematic review and meta-analysis. Medicine (Baltimore) 2019; 98 (50) e18348
40 Fu P, Gao M, Yung KKL. Association of Intestinal Disorders with Parkinson’s Disease and Alzheimer’s Disease: A Systematic Review and Meta-Analysis. ACS Chem Neurosci 2020; 11 (03) 395-405
41 Cardenas VM, Boller F, Roman GC. Helicobacter pylori, Vascular Risk Factors and Cognition in U.S. Older Adults. Brain Sci 2019; 9 (12) 370
42 Dardiotis E, Sokratous M, Tsouris Z. et al. Association between Helicobacter pylori infection and Guillain-Barre Syndrome: A meta-analysis. Eur J Clin Invest 2020; 50 (05) e13218
43 Xiong LJ, Mao M. Current views of the relationship between Helicobacter pylori and Henoch-Schonlein purpura in children. World J Clin Pediatr 2016; 5 (01) 82-88
44 Hooi JKY, Lai WY, Ng WK. et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153 (02) 420-429
45 Wex T, Venerito M, Kreutzer J. et al. Serological prevalence of Helicobacter pylori infection in Saxony-Anhalt, Germany, in 2010. Clin Vaccine Immunol 2011; 18 (12) 2109-2112
46 Michel A, Pawlita M, Boeing H. et al. Helicobacter pylori antibody patterns in Germany: a cross-sectional population study. Gut Pathog 2014; 6: 10
47 Franck C, Hoffmann A, Link A. et al. Prevalence of Helicobacter pylori infection among blood donors in Saxony-Anhalt, Germany–a region at intermediate risk for gastric cancer. Zeitschrift für Gastroenterologie 2017; 55 (07) 653-656
48 Weyermann M, Rothenbacher D, Brenner H. Acquisition of Helicobacter Pylori Infection in Early Childhood: Independent Contributions of Infected Mothers, Fathers and Siblings. The American Journal of Gastroenterology 2008; 104 (01) 182-189
49 Grimm W, Fischbach W. Helicobacter pylori infection in children and juveniles: an epidemiological study on prevalence, socio-economic factors and symptoms. Dtsch Med Wochenschr 2003; 128 (37) 1878-1883
50 Graham DY, Malaty HM, Evans DG. et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Gastroenterology 1991; 100 (06) 1495-1501
51 Malaty HM, Evans DG, Evans DJ. et al. Helicobacter pylori in hispanics: Comparison with blacks and whites of similar age and socioeconomic class. Gastroenterology 1992; 103 (03) 813-816
52 Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994; 35 (06) 742-745
53 Perez-Perez GI, Olivares AZ, Foo FY. Seroprevalence of Helicobacter pylori in New York City populations originating in East Asia. J Urban Health 2005; 82 (03) 510-516
54 Malaty HM, Kim JG, Kim SD. et al. Prevalence of Helicobacter pylori infection in Korean children: inverse relation to socioeconomic status despite a uniformly high prevalence in adults. Am J Epidemiol 1996; 143 (03) 257-262
55 Nouraie M, Latifi-Navid S, Rezvan H. et al. Childhood hygienic practice and family education status determine the prevalence of Helicobacter pylori infection in Iran. Helicobacter 2009; 14 (01) 40-46
56 Mayerle J, den Hoed CM, Schurmann C. et al. Identification of genetic loci associated with Helicobacter pylori serologic status. JAMA 2013; 309 (18) 1912-1920
57 Ikehara Y, Nishihara S, Yasutomi H. et al. Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG antibody. Cancer Epidemiol Biomarkers Prev 2001; 10 (09) 971-977
58 Banatvala N, Mayo K, Megraud F. et al. The cohort effect and Helicobacter pylori. J Infect Dis 1993; 168 (01) 219-221
59 Roosendaal R, Kuipers EJ, Buitenwerf J. et al. Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 1997; 92 (09) 1480-1482
60 den Hoed CM, Vila AJ, Holster IL. et al. Helicobacter pylori and the birth cohort effect: evidence for stabilized colonization rates in childhood. Helicobacter 2011; 16 (05) 405-409
61 Rokkas T, Sechopoulos P, Pistiolas D. et al. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol 2010; 22 (09) 1128-1133
62 Lei G, Melanie NW, Elke R. et al. Sibship size, Helicobacter pylori infection and chronic atrophic gastritis: A population-based study among 9444 older adults from Germany. International Journal of Epidemiology 2010; 39: 129-134
63 Porsch-Ozcürümez M, Doppl W, Hardt PD. et al. Impact of migration on Helicobacter pylori seroprevalence in the offspring of Turkish immigrants in Germany. Turk J Pediatr 2003; 45 (03) 203-208
64 Wu Y, Murray GK, Byrne EM. et al. “GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression.”. Nat Commun 2021; 12 (01) 1146
65 Odenbreit S, Püls J, Sedlmaier B. et al. “Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion.”. Science 2000; 287: 1497-1500
66 Link A, Langner C, Schirrmeister W. et al. Helicobacter pylori vacA genotype is a predominant determinant of immune response to Helicobacter pylori CagA. World J Gastroenterol 2017; 23 (26) 4712-4723
67 Gutwerk A, Wex T, Stein K. et al. Helicobacter Pylori Serology in Relation to Hepatitis C Virus Infection and IL28B Single Nucleotide Polymorphism. J Clin Med 2018; 7 (03) 44
68 Basso D, Zambon CF, Letley DP. et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 2008; 135 (01) 91-99
69 Tindberg Y, Bengtsson C, Granath F. et al. Helicobacter pylori infection in Swedish school children: lack of evidence of child-to-child transmission outside the family. Gastroenterology 2001; 121 (02) 310-316
70 Rothenbacher D, Winkler M, Gonser T. et al. Role of infected parents in transmission of helicobacter pylori to their children. Pediatr Infect Dis J 2002; 21 (07) 674-679
71 Rocha GA, Rocha AM, Silva LD. et al. Transmission of Helicobacter pylori infection in families of preschool-aged children from Minas Gerais, Brazil. Trop Med Int Health 2003; 8 (11) 987-991
72 Kivi M, Johansson AL, Reilly M. et al. Helicobacter pylori status in family members as risk factors for infection in children. Epidemiol Infect 2005; 133 (04) 645-652
73 Han SR, Zschausch HC, Meyer HG. et al. Helicobacter pylori: clonal population structure and restricted transmission within families revealed by molecular typing. J Clin Microbiol 2000; 38 (10) 3646-3651
74 Kivi M, Johansson AL, Sorberg M. et al. Concordance of Helicobactrer pylori strainsw within families. J Clin Microbiol 2003; 41 (12) 5604-5608
75 Dolan B, Burkitt-Gray L, Shovelin S. et al. The use of stool specimens reveals Helicobacter pylori strain diversity in a cohort of adolescents and their family members in a developed country. Int J Med Microbiol 2018; 308 (02) 247-255
76 Mendall MA, Goggin PM, Molineaux N. et al. Childhood living conditions and Helicobacter pylori seropositivity in adult life. Lancet 1992; 339: 896-897
77 Carter F, Seaton T, Yuan Y. et al. Prevalence of Helicobacter pylori infection in children in the Bahamas. West Indian Med J 2023; 61 (07) 698-702
78 Jafar S, Jalil A, Soheila N. et al. Prevalence of helicobacter pylori infection in children, a population-based cross-sectional study in west iran. Iran J Pediatr 2013; 23 (01) 13-18
79 Goodman KJ, Correa P. Transmission of Helicobacter pylori among siblings. The Lancet 2000; 355: 358-362
80 Rowland M, Daly L, Vaughan M. et al. Age-specific incidence of Helicobacter pylori. Gastroenterology 2006; 130 (01) 65-72; quiz 211
81 Osaki T, Zaman C, Yonezawa H. et al. Influence of Intestinal Indigenous Microbiota on Intrafamilial Infection by Helicobacter pylori in Japan. Front Immunol 2018; 9: 287
82 Bastos J, Carreira H, La Vecchia C. et al. Childcare attendance and Helicobacter pylori infection. European Journal of Cancer Prevention 2013; 22 (04) 311-319
83 Luman W, Zhao Y, Ng HS. et al. Helicobacter pylori infection is unlikely to be transmitted between partners: evidence from genotypic study in partners of infected patients. Eur J Gastroenterol Hepatol 2002; 14 (05) 521-528
84 Stone MA, Taub N, Barnett DB. et al. Increased risk of infection with Helicobacter pylori in spouses of infected subjects: observations in a general population sample from the UK. Hepatogastroenterology 2000; 47 (32) 433-436
85 Brenner H, Weyermann M, Rothenbacher D. Clustering of Helicobacter pylori infection in couples: differences between high- and low-prevalence population groups. Ann Epidemiol 2006; 16 (07) 516-520
86 Sgambato D, Visciola G, Ferrante E. et al. Prevalence of Helicobacter pylori infection in sexual partners of H. pylori-infected subjects: Role of gastroesophageal reflux. United European Gastroenterol J 2018; 6 (10) 1470-1476
87 Zhou LY, Song ZQ, Xue Y. et al. Recurrence of Helicobacter pylori infection and the affecting factors: A follow-up study. J Dig Dis 2017; 18 (01) 47-55
88 Zhou G. Helicobacter pylori Recurrence after Eradication Therapy in Jiangjin District, Chongqing, China. Gastroenterol Res Pract 2020; 2020: 7510872
89 Parsonnet J, Hansen S, Rodriguez L. et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330 (18) 1267-1271
90 Castro-Munoz LJ, Gonzalez-Diaz CA, Munoz-Escobar A. et al. Prevalence of Helicobacter pylori from the oral cavity of Mexican asymptomatic children under 5 years of age through PCR. Arch Oral Biol 2017; 73: 55-59
91 Vasapolli R, Schutte K, Schulz C. et al. Analysis of Transcriptionally Active Bacteria Throughout the Gastrointestinal Tract of Healthy Individuals. Gastroenterology 2019; 157 (04) 1081-1098.e3
92 Leung WK, Siu KL, Kwok CK. et al. Isolation of Helicobacter pylori from vomitus in children and its implication in gastro-oral transmission. Am J Gastroenterol 1999; 94 (10) 2881-2884
93 Laporte R, Pernes P, Pronnier P. et al. Acquisition of Helicobacter pylori infection after outbreaks of gastroenteritis: prospective cohort survey in institutionalised young people. Bmj 2004; 329: 204-205
94 Schulz C, Schutte K, Koch N. et al. The active bacterial assemblages of the upper GI tract in individuals with and without Helicobacter infection. Gut 2018; 67 (02) 216-225
95 Chen Z, Cai J, Chen YM. et al. A meta-analysis of the association between the presence of Helicobacter pylori and periodontal diseases. Medicine (Baltimore) 2019; 98 (22) e15922
96 Wei X, Zhao HQ, Ma C. et al. The association between chronic periodontitis and oral Helicobacter pylori: A meta-analysis. PLoS One 2019; 14 (12) e0225247
97 Payao SL, Rasmussen LT. Helicobacter pylori and its reservoirs: A correlation with the gastric infection. World J Gastrointest Pharmacol Ther 2016; 7 (01) 126-132
98 Moreira ED, Nassri VB, Santos RS. et al. Association of Helicobacter pylori infection and giardiasis: results from a study of surrogate markers for fecal exposure among children. World J Gastroenterol 2005; 11 (18) 2759-2763
99 Bui D, Brown HE, Harris RB. et al. Serologic Evidence for Fecal-Oral Transmission of Helicobacter pylori. Am J Trop Med Hyg 2016; 94 (01) 82-88
100 Klein PD, Graham DY, Gaillour A. et al. Water source as risk factor for Helicobacter pylori infection in Peruvian children. Gastrointestinal Physiology Working Group. Lancet 1991; 337: 1503-1506
101 Nurgalieva ZZ, Malaty HM, Graham DY. et al. Helicobacter pylori infection in Kazakhstan: effect of water source and household hygiene. Am J Trop Med Hyg 2002; 67 (02) 201-206
102 Aziz RK, Khalifa MM, Sharaf RR. Contaminated water as a source of Helicobacter pylori infection: A review. J Adv Res 2015; 6 (04) 539-547
103 Farhadkhani M, Nikaeen M, Hassanzadeh A. et al. Potential transmission sources of Helicobacter pylori infection: detection of H. pylori in various environmental samples. J Environ Health Sci Eng 2019; 17 (01) 129-113
104 Hulten K, Han SW, Enroth H. et al. Helicobacter pylori in the drinking water in Peru. Gastroenterology 1996; 110 (04) 1031-1035
105 Lu Y, Redlinger TE, Avitia R. et al. Isolation and genotyping of Helicobacter pylori from untreated municipal wastewater. Appl Environ Microbiol 2002; 68 (03) 1436-1439
106 Bai X, Xi C, Wu J. Survival of Helicobacter pylori in the wastewater treatment process and the receiving river in Michigan, USA. J Water Health 2016; 14 (04) 692-698
107 Ranjbar R, Khamesipour F, Jonaidi-Jafari N. et al. Helicobacter pylori in bottled mineral water: genotyping and antimicrobial resistance properties. BMC Microbiol 2016; 16: 40
108 Dore MP, Sepulveda AR, Osato MS. et al. Helicobacter pylori in sheep milk. The Lancet 1999; 354
109 Dore MP, Sepulveda AR, El-Zimaity H. et al. Isolation of Helicobacter pylori from sheep-implications for transmission to humans. Am J Gastroenterol 2001; 96 (05) 1396-1401
110 Zamani M, Vahedi A, Maghdouri Z. et al. Role of food in environmental transmission of Helicobacter pylori. Caspian J Intern Med 2017; 8 (03) 146-152
111 Siavoshi F, Sahraee M, Ebrahimi H. et al. Natural fruits, flowers, honey, and honeybees harbor Helicobacter pylori-positive yeasts. Helicobacter 2018; 23 (02) e12471
112 Dubois A, Fiala N, Heman-Ackah LM. et al. Natural gastric infection with Helicobacter pylori in monkeys: a model for spiral bacteria infection in humans. Gastroenterology 1994; 106 (06) 1405-1417
113 Handt LK, Fox JG, Dewhirst FE. et al. Helicobacter pylori isolated from the domestic cat: public health implications. Infect Immun 1994; 62 (06) 2367-2374
114 Momtaz H, Dabiri H, Souod N. et al. Study of Helicobacter pylori genotype status in cows, sheep, goats and human beings. BMC Gastroenterol 2014; 14: 61
115 Junqueira ACM, Ratan A, Acerbi E. et al. The microbiomes of blowflies and houseflies as bacterial transmission reservoirs. Sci Rep 2017; 7 (01) 16324
116 Kheyre H, Morais S, Ferro A. et al. The occupational risk of Helicobacter pylori infection: a systematic review. Int Arch Occup Environ Health 2018; 91 (06) 657-674
117 Kim HY, Kim N, Kim SM. et al. Seroprevalence of Helicobacter pylori Infection in Korean Health Personnel. Gut Liver 2013; 7 (06) 648-654
118 Peters C, Schablon A, Harling M. et al. The occupational risk of Helicobacter pylori infection among gastroenterologists and their assistants. BMC Infect Dis 2011; 11: 154
119 Sjomina O, Pavlova J, Niv Y. et al. Epidemiology of Helicobacter pylori infection. Helicobacter 2018; 23 (Suppl. 01) e12514
120 Take S, Mizuno M, Ishiki K. et al. Reinfection rate of Helicobacter pylori after eradication treatment: a long-term prospective study in Japan. J Gastroenterol 2012; 47 (06) 641-646
121 Knippig C, Arand F, Leodolter A. et al. Prevalence of H. pylori-infection in family members of H. pylori positive and its influence on the reinfection rate after successful eradication therapy: a two-year follow-up. Z Gastroenterol 2002; 40 (06) 383-387
122 Hu Y, Wan JH, Li XY. et al. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther 2017; 46 (09) 773-779
123 Gebara EC, Faria CM, Pannuti C. et al. Persistence of Helicobacter pylori in the oral cavity after systemic eradication therapy. J Clin Periodontol 2006; 33 (05) 329-333
124 Sun Y, Zhang J. Helicobacter pylori recrudescence and its influencing factors. J Cell Mol Med 2019; 23 (12) 7919-7925
125 Zhang Y, Dong Q, Tian L. et al. Risk factors for recurrence of Helicobacter pylori infection after successful eradication in Chinese children: A prospective, nested case-control study. Helicobacter 2020; 25 (05) e12749
126 Goodman KJ, O’Rourke K, Day RS. et al. Dynamics of Helicobacter pylori infection in a US-Mexico cohort during the first two years of life. Int J Epidemiol 2005; 34 (06) 1348-1355
127 Rehmann A, Muller D, Krumbiegel P. et al. Spontaneous elimination of helicobacter pylori infection in children. Klin Padiatr 2005; 217 (01) 15-17
128 Zhou Y, Ye Z, Huang J. et al. High prevalence and low spontaneous eradication rate of Helicobacter pylori infection among schoolchildren aged 7–12 years. Acta Paediatr 2018;
129 Duque X, Vilchis J, Mera R. et al. Natural history of Helicobacter pylori infection in Mexican schoolchildren: incidence and spontaneous clearance. J Pediatr Gastroenterol Nutr 2012; 55 (02) 209-216
130 Broussard CS, Goodman KJ, Phillips CV. et al. Antibiotics taken for other illnesses and spontaneous clearance of Helicobacter pylori infection in children. Pharmacoepidemiol Drug Saf 2009; 18 (08) 722-729
131 Luzza F, Suraci E, Larussa T. et al. High exposure, spontaneous clearance, and low incidence of active Helicobacter pylori infection: the Sorbo San Basile study. Helicobacter 2014; 19 (04) 296-305
132 Danesh J, Appleby P, Peto R. How often does surgery for peptic ulceration eradicate Helicobacter pylori? Systematic review of 36 studies. Bmj 1998; 316: 746-747
133 Bair MJ, Wu MS, Chang WH. et al. Spontaneous clearance of Helicobacter pylori colonization in patients with partial gastrectomy: correlates with operative procedures and duration after operation. J Formos Med Assoc 2009; 108 (01) 13-19
134 Suh S, Nah JC, Uhm MS. et al. Changes in prevalence of Helicobacter pylori infection after subtotal gastrectomy. Hepatogastroenterology 2012; 59 (114) 646-648
135 Yoon K, Kim N, Kim J. et al. Dynamic Changes in Helicobacter pylori Status Following Gastric Cancer Surgery. Gut Liver 2017; 11 (02) 209-215
136 Lin YS, Chen MJ, Shih SC. et al. Management of Helicobacter pylori infection after gastric surgery. World J Gastroenterol 2014; 20 (18) 5274-5282
137 O’Connor HJ, Dixon MF, Wyatt JI. et al. Effect of duodenal ulcer surgery and enterogastric reflux on Campylobacter pyloridis. Lancet 1986; 2: 1178-1181
138 Venerito M, Radunz M, Reschke K. et al. Autoimmune gastritis in autoimmune thyroid disease. Aliment Pharmacol Ther 2015; 41 (07) 686-693
139 Weise F, Vieth M, Reinhold D. et al. Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the star project on gastric cancer research. United European Gastroenterol J 2020; 8 (02) 175-184
140 Malfertheiner P, Selgrad M, Wex T. et al. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. The Lancet Gastroenterology & Hepatology 2018; 3 (10) 698-707
141 Zeng M, Mao XH, Li JX. et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2015; 386: 1457-1464
142 Cutler AF, Havstad S, Ma CK. et al. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology 1995; 109 (01) 136-141
143 Thijs JC, van Zwet AA, Thijs WJ. et al. Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. Am J Gastroenterol 1996; 91 (10) 2125-2129
144 Laheij RJ, de Boer WA, Jansen JB. et al. Diagnostic performance of biopsy-based methods for determination of Helicobacter pylori infection without a reference standard. J Clin Epidemiol 2000; 53 (07) 742-746
145 Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101 (08) 1921-1930
146 Calvet X, Lario S, Ramirez-Lazaro MJ. et al. Comparative accuracy of 3 monoclonal stool tests for diagnosis of Helicobacter pylori infection among patients with dyspepsia. Clin Infect Dis 2010; 50 (03) 323-328
147 Deguchi R, Matsushima M, Suzuki T. et al. Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy. J Gastroenterol 2009; 44 (07) 713-716
148 Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection -- a critical review. Aliment Pharmacol Ther 2004; 20 (10) 1001-1017
149 Korkmaz H, Kesli R, Karabagli P. et al. Comparison of the diagnostic accuracy of five different stool antigen tests for the diagnosis of Helicobacter pylori infection. Helicobacter 2013; 18 (05) 384-391
150 Lario S, Ramirez-Lazaro MJ, Montserrat A. et al. Diagnostic accuracy of three monoclonal stool tests in a large series of untreated Helicobacter pylori infected patients. Clin Biochem 2016; 49 (09) 682-687
151 Fang YJ, Chen MJ, Chen CC. et al. Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan. J Formos Med Assoc 2020; 119 (11) 1626-1633
152 Veijola L, Myllyluoma E, Korpela R. et al. Stool antigen tests in the diagnosis of Helicobacter pylori infection before and after eradication therapy. World J Gastroenterol 2005; 11 (46) 7340-7344
153 Gatta L, Perna F, Ricci C. et al. A rapid immunochromatographic assay for Helicobacter pylori in stool before and after treatment. Aliment Pharmacol Ther 2004; 20 (04) 469-474
154 Best LM, Takwoingi Y, Siddique S. et al. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev 2018; 3: CD012080
155 Formichella L, Romberg L, Bolz C. et al. A novel line immunoassay based on recombinant virulence factors enables highly specific and sensitive serologic diagnosis of Helicobacter pylori infection. Clin Vaccine Immunol 2013; 20 (11) 1703-1710
156 Skrebinska S, Daugule I, Santare D. et al. Accuracy of two plasma antibody tests and faecal antigen test for non-invasive detection of H. pylori in middle-aged Caucasian general population sample. Scand J Gastroenterol 2018; 53 (07) 777-783
157 Schulz C, Kalali B, Vasapolli R. et al. New accurate Helicobacter pylori rapid blood test based on combined FliD and CagA antibodies [accepted for conference presentation]. Digestive Disease Week 2021;
158 Gong Y, Li Q, Yuan Y. Accuracy of testing for anti-Helicobacter pylori IgG in urine for H. pylori infection diagnosis: a systematic review and meta-analysis. BMJ Open 2017; 7 (04) e013248
159 Sjomina O, Pavlova J, Niv Y. et al. Epidemiology of Helicobacter pylori infection. Helicobacter 2018; 23 (Suppl. 01) e12514
160 Venneman K, Huybrechts I, Gunter MJ. et al. The epidemiology of Helicobacter pylori infection in Europe and the impact of lifestyle on its natural evolution toward stomach cancer after infection: A systematic review. Helicobacter 2018; 23 (03) e12483
161 Dixon MF, Genta RM, Yardley JH. et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20 (10) 1161-1181
162 Genta RM, Graham DY. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc 1994; 40 (03) 342-345
163 El-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. Hum Pathol 1999; 30 (01) 72-77
164 Sudraba A, Daugule I, Rudzite D. et al. Performance of routine Helicobacter pylori tests in patients with atrophic gastritis. J Gastrointestin Liver Dis 2011; 20 (04) 349-354
165 Lan HC, Chen TS, Li AF. et al. Additional corpus biopsy enhances the detection of Helicobacter pylori infection in a background of gastritis with atrophy. BMC Gastroenterol 2012; 12: 182
166 Craanen ME, Blok P, Dekker W. et al. Subtypes of intestinal metaplasia and Helicobacter pylori. Gut 1992; 33 (05) 597-600
167 Stolte M, Muller H, Talley NJ. et al. In patients with Helicobacter pylori gastritis and functional dyspepsia, a biopsy from the incisura angularis provides useful diagnostic information. Pathol Res Pract 2006; 202 (06) 405-413
168 Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacterand Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019; 51: 365-388
169 Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol 2005; 36 (03) 228-233
170 Ono S, Dohi O, Yagi N. et al. Accuracies of Endoscopic Diagnosis of Helicobacter pylori-Gastritis: Multicenter Prospective Study Using White Light Imaging and Linked Color Imaging. Digestion 2020; 101 (05) 624-630
171 East JE, Vleugels JL, Roelandt P. et al. Advanced endoscopic imaging: European Society of Gastrointestinal Endoscopy (ESGE) Technology Review. Endoscopy 2016; 48 (11) 1029-1045
172 Banks M, Graham D, Jansen M. et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut 2019; 68 (09) 1545-1575
173 Gupta S, Li D, El Serag HB. et al. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology 2020; 158 (03) 693-702
174 Laine L, Lewin DN, Naritoku W. et al. Prospective comparison of H&E, Giemsa, and Genta stains for the diagnosis of Helicobacter pylori. Gastrointest Endosc 1997; 45 (06) 463-467
175 Fallone CA, Loo VG, Lough J. et al. Hematoxylin and eosin staining of gastric tissue for the detection of Helicobacter pylori. Helicobacter 1997; 2 (01) 32-35
176 Graham DY, Miftahussurur M. Helicobacter pylori urease for diagnosis of Helicobacter pylori infection: A mini review. Journal of advanced research 2018; 13: 51-57
177 Guidelines for clinical trials in Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group. Gut 1997; 41 (Suppl. 02) S1-S9
178 Parihar V, Holleran G, Hall B. et al. A combined antral and corpus rapid urease testing protocol can increase diagnostic accuracy despite a low prevalence of Helicobacter pylori infection in patients undergoing routine gastroscopy. United European Gastroenterol J 2015; 3 (05) 432-436
179 Uotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test. Annals of translational medicine 2015; 3 (01) 9
180 Moon SW, Kim TH, Kim HS. et al. United Rapid Urease Test Is Superior than Separate Test in Detecting Helicobacter pylori at the Gastric Antrum and Body Specimens. Clinical endoscopy 2012; 45 (04) 392-396
181 Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20 (02) 280-322
182 Selgrad M, Tammer I, Langner C. et al. Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of Helicobacter pylori infection. World J Gastroenterol 2014; 20 (43) 16245-16251
183 Ailloud F, Didelot X, Woltemate S. et al. Within-host evolution of Helicobacter pylori shaped by niche-specific adaptation, intragastric migrations and selective sweeps. Nat Commun 2019; 10 (01) 2273
184 McNicholl AG, Ducons J, Barrio J. et al. Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection. Gastroenterologia y hepatologia 2017; 40 (10) 651-657
185 Dechant FX, Dechant R, Kandulski A. et al. Accuracy of Different Rapid Urease Tests in Comparison with Histopathology in Patients with Endoscopic Signs of Gastritis. Digestion 2020; 101 (02) 184-190
186 Koumi A, Filippidis T, Leontara V. et al. Detection of Helicobacter pylori: A faster urease test can save resources. World J Gastroenterol 2011; 17 (03) 349-353
187 Perna F, Ricci C, Gatta L. et al. Diagnostic accuracy of a new rapid urease test (Pronto Dry), before and after treatment of Helicobacter pylori infection. Minerva gastroenterologica e dietologica 2005; 51 (03) 247-254
188 Brandi G, Biavati B, Calabrese C. et al. Urease-positive bacteria other than Helicobacter pylori in human gastric juice and mucosa. Am J Gastroenterol 2006; 101 (08) 1756-1761
189 Ramírez-Lázaro MJ, Lario S, Calvet X. et al. Occult H. pylori infection partially explains “false-positive” results of (13)C-urea breath test. United European Gastroenterol J 2015; 3 (05) 437-442
190 Lo CC, Lai KH, Peng NJ. et al. Polymerase chain reaction: a sensitive method for detecting Helicobacter pylori infection in bleeding peptic ulcers. World J Gastroenterol 2005; 11 (25) 3909-3914
191 Ramírez-Lázaro MJ, Lario S, Casalots A. et al. Real-time PCR improves Helicobacter pylori detection in patients with peptic ulcer bleeding. PLoS One 2011; 6 (05) e20009
192 Saez J, Belda S, Santibáñez M. et al. Real-time PCR for diagnosing Helicobacter pylori infection in patients with upper gastrointestinal bleeding: comparison with other classical diagnostic methods. J Clin Microbiol 2012; 50 (10) 3233-3237
193 Bénéjat L, Ducournau A, Lehours P. et al. Real-time PCR for Helicobacter pylori diagnosis. The best tools available. Helicobacter 2018; 23 (05) e12512
194 Hyde DK, Lee J, Buckley M. et al. Evaluation of antral biopsies used in the rapid urease test for Helicobacter pylori culture. Eur J Clin Microbiol Infect Dis 1999; 18 (01) 73-75
195 Chung WC, Jeon EJ, Oh JH. et al. Dual-priming oligonucleotide-based multiplex PCR using tissue samples from the rapid urease test kit for the detection of Helicobacter pylori in bleeding peptic ulcers. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2016; 48 (08) 899-903
196 Milani M, Moaddab Y, Sharifi Y. One piece biopsy for both rapid urease test and cultivation of Helicobacter pylori. J Microbiol Methods 2019; 164: 105674
197 Urita Y, Hike K, Torii N. et al. Influence of urease activity in the intestinal tract on the results of 13C-urea breath test. J Gastroenterol Hepatol 2006; 21 (04) 744-747
198 Gurbuz AK, Ozel AM, Narin Y. et al. Is the remarkable contradiction between histology and 14C urea breath test in the detection of Helicobacter pylori due to false-negative histology or false-positive 14C urea breath test?. The Journal of international medical research 2005; 33 (06) 632-640
199 Osaki T, Mabe K, Hanawa T. et al. Urease-positive bacteria in the stomach induce a false-positive reaction in a urea breath test for diagnosis of Helicobacter pylori infection. J Med Microbiol 2008; 57 (07) 814-819
200 Arroyo Vázquez JA, Henning C, Park PO. et al. Bacterial colonization of the stomach and duodenum in a Swedish population with and without proton pump inhibitor treatment. JGH open: an open access journal of gastroenterology and hepatology 2020; 4 (03) 405-409
201 Del Piano M, Anderloni A, Balzarini M. et al. The innovative potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and Lactobacillus delbrueckii Subsp. delbrueckii LDD01 to restore the “gastric barrier effect” in patients chronically treated with PPI: a pilot study. J Clin Gastroenterol 2012; 46: S18-S26
202 Del Piano M, Pagliarulo M, Tari R. et al. Correlation between chronic treatment with proton pump inhibitors and bacterial overgrowth in the stomach: any possible beneficial role for selected lactobacilli?. J Clin Gastroenterol 2014; 48 (Suppl. 01) S40-S46
203 Levine A, Shevah O, Shabat-Sehayek V. et al. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. Aliment Pharmacol Ther 2004; 20 (01) 117-122
204 Capurso G, Carnuccio A, Lahner E. et al. Corpus-predominant gastritis as a risk factor for false-negative 13C-urea breath test results. Aliment Pharmacol Ther 2006; 24 (10) 1453-1460
205 Lehours P, Ruskone-Fourmestraux A, Lavergne A. et al. Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma?. Am J Gastroenterol 2003; 98 (02) 291-295
206 Vörhendi N, Soós A, Anne Engh M. et al. Accuracy of the Helicobacter pylori diagnostic tests in patients with peptic ulcer bleeding: a systematic review and network meta-analysis. Therap Adv Gastroenterol 2020; 13: 1756284820965324
207 Peitz U, Leodolter A, Kahl S. et al. Antigen stool test for assessment of Helicobacter pylori infection in patients with upper gastrointestinal bleeding. Alimentary pharmacology & therapeutics 2003; 17 (08) 1075-1084
208 Rimbara E, Sasatsu M, Graham DY. PCR detection of Helicobacter pylori in clinical samples. Methods Mol Biol 2013; 943: 279-287
209 Choi YJ, Kim N, Lim J. et al. Accuracy of diagnostic tests for Helicobacter pylori in patients with peptic ulcer bleeding. Helicobacter 2012; 17 (02) 77-85
210 van Leerdam ME, van der Ende A, ten Kate FJ. et al. Lack of accuracy of the noninvasive Helicobacter pylori stool antigen test in patients with gastroduodenal ulcer bleeding. The American journal of gastroenterology 2003; 98 (04) 798-801
211 Kim JJ, Lee JS, Olafsson S. et al. Low adherence to Helicobacter pylori testing in hospitalized patients with bleeding peptic ulcer disease. Helicobacter 2014; 19 (02) 98-104
212 Sánchez-Delgado J, Gené E, Suárez D. et al. Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. The American journal of gastroenterology 2011; 106 (03) 398-405
213 Sung JJY, Laine L, Kuipers EJ. et al. Towards personalised management for non-variceal upper gastrointestinal bleeding. Gut 2021; 70: 818-824
214 Tian XY, Zhu H, Zhao J. et al. Diagnostic performance of urea breath test, rapid urea test, and histology for Helicobacter pylori infection in patients with partial gastrectomy: a meta-analysis. J Clin Gastroenterol 2012; 46 (04) 285-292
215 Gatta L, Vakil N, Ricci C. et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004; 99 (05) 823-829
216 Malfertheiner P. Diagnostic methods for H. pylori infection: Choices, opportunities and pitfalls. United European Gastroenterol J 2015; 3 (05) 429-431
217 Stoschus B, Domínguez-Muñoz JE, Kalhori N. et al. Effect of omeprazole on Helicobacter pylori urease activity in vivo. Eur J Gastroenterol Hepatol 1996; 8 (08) 811-813
218 Parente F, Sainaghi M, Sangaletti O. et al. Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test. Aliment Pharmacol Ther 2002; 16 (03) 553-557
219 Kodama M, Murakami K, Okimoto T. et al. Influence of proton pump inhibitor treatment on Helicobacter pylori stool antigen test. World J Gastroenterol 2012; 18 (01) 44-48
220 Savarino V, Bisso G, Pivari M. et al. Effect of gastric acid suppression on 13C-urea breath test: comparison of ranitidine with omeprazole. Aliment Pharmacol Ther 2000; 14 (03) 291-297
221 Murakami K, Sato R, Okimoto T. et al. Influence of anti-ulcer drugs used in Japan on the result of (13)C-urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol 2003; 38 (10) 937-941
222 Shimoyama T, Kato C, Kodama M. et al. Applicability of a monoclonal antibody-based stool antigen test to evaluate the results of Helicobacter pylori eradication therapy. Japanese journal of infectious diseases 2009; 62 (03) 225-227
223 Haley KP, Gaddy JA. Helicobacter pylori: Genomic Insight into the Host-Pathogen Interaction. International journal of genomics 2015; 2015: 386905
224 Wüppenhorst N, Draeger S, Stüger HP. et al. Prospective multicentre study on antimicrobial resistance of Helicobacter pylori in Germany. J Antimicrob Chemother 2014; 69 (11) 3127-3133
225 Hofreuter D, Behrendt J, Franz A. et al. Antimicrobial resistance of Helicobacter pylori in an eastern German region. Helicobacter 2021; 26 (01) e12765
226 Mégraud F, Bruyndonckx R, Coenen S. et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Manuscript submitted for publication 2021;
227 Wueppenhorst N, Stueger HP, Kist M. et al. High secondary resistance to quinolones in German Helicobacter pylori clinical isolates. J Antimicrob Chemother 2013; 68 (07) 1562-1566
228 Best LM, Haldane DJ, Keelan M. et al. Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother 2003; 47 (10) 3138-3144
229 Grignon B, Tankovic J, Mégraud F. et al. Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori. Microbial drug resistance (Larchmont, NY) 2002; 8 (01) 61-66
230 Perna F, Gatta L, Figura N. et al. Susceptibility of Helicobacter pylori to metronidazole. Am J Gastroenterol 2003; 98 (10) 2157-2161
231 Schmitt BH, Regner M, Mangold KA. et al. PCR detection of clarithromycin-susceptible and -resistant Helicobacter pylori from formalin-fixed, paraffin-embedded gastric biopsies. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2013; 26 (09) 1222-1227
232 Cambau E, Allerheiligen V, Coulon C. et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 2009; 47 (11) 3600-3607
233 Oleastro M, Ménard A, Santos A. et al. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol 2003; 41 (01) 397-402
234 Miendje Deyi VY, Burette A, Bentatou Z. et al. Practical use of GenoType HelicoDR, a molecular test for Helicobacter pylori detection and susceptibility testing. Diagn Microbiol Infect Dis 2011; 70 (04) 557-560
235 Liou JM, Chen CC, Chang CY. et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68 (02) 450-456
236 Lauener FN, Imkamp F, Lehours P. et al. Genetic Determinants and Prediction of Antibiotic Resistance Phenotypes in Helicobacter pylori. Journal of clinical medicine 2019; 8 (01)
237 Ford AC, Delaney BC, Forman D. et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006; (02) CD003840
238 Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93 (09) 1409-1415
239 Leodolter A, Kulig M, Brasch H. et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15 (12) 1949-1958
240 Liu CC, Lee CL, Chan CC. et al. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study. Arch Intern Med 2003; 163 (17) 2020-2024
241 Malfertheiner P, Megraud F, O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56 (06) 772-781
242 Sharma VK, Sahai AV, Corder FA. et al. Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage. Aliment Pharmacol Ther 2001; 15 (12) 1939-1947
243 Sonnenberg A, Olson CA, Zhang J. The effect of antibiotic therapy on bleeding from duodenal ulcer. Am J Gastroenterol 1999; 94 (04) 950-954
244 Ford AC, Gurusamy KS, Delaney B. et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev 2016; 4 (04) CD003840
245 Götz M, Anders M, Biecker E. et al. S2k Leitlinie Gastrointestinale Blutung. Z Gastroenterol 2017; 55: 883-936
246 Banerjee S, Cash BC, Dominitz JA. et al. ASGE Practice Guideline: The role of endoscopy in the management of peptic ulcer disease. Gastrointest Endosc 2010; 71 (04) 663-668
247 Gielisse EAR, Kuyvenhoven JP. Follow-up endoscopy for benign-appearing gastric ulcers has no additive value in detecting malignancy. Gastric Cancer 2015; 18 (04) 803-809
248 Lee YB, Han J, Cho JH. et al. Clinicasl outcomes of endoscopic surveillance for gastric ulcers in populations with a high prevalence of gastric cancer. Turk J Gastroenterol 2016; 27 (05) 421-427
249 Rodriguez-de-Santiago E, Frazzoni L, Fuccio L. et al. Digestive findings that do not require endoscopic surveillance – Reducing the burden of care: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2020; 52 (06) 491-497
250 Chey WD, Leontiadis GI, Howden CW. et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112: 212-238
251 El-Serag HB, Kao JY, Kanwal F. et al. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clin Gastroenterol Hepatol 2018; 16 (07) 992-1002
252 Sindel A, Al-Juhaishi T, Yazbeck V. Marginal zone lymphoma: State-of-the-art treatment. Curr Treat Options Oncol 2019; 20 (12) 90
253 Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood 2016; 127 (17) 2082-2092
254 Ruskoné-Fourmestraux A, Fischbach W, Aleman BMP. et al. EGILS consensus report. Gastric extranodal marginal zone B cell lymphoma of MALT. Gut 2011; 60: 747-758
255 Zullo A, Hassan C, Cristofari F. et al. Effects of Helicobacter pylori Eradication on Early Stage Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Clin Gastroenterol Hepatol 2010; 8: 105-110
256 Fischbach W, Goebeler-Kolve ME, Dragosics B. et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication: experience from a large prospective series. GUT 2004; 53: 34-37
257 Wündisch T, Dieckhoff P, Greene B. et al. Second cancers and Residual Disease in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma by Helicobacter pylori Eradication and Followed for 10 Years. Gastroenterology 2012; 143: 936-942
258 Zullo A, Hassan C, Ridola L. et al. Eradication Therapy in Helicobacter pylori-negative, gastric low-grade Mucosa-associated Lymphoid Tissue lymphoma patients. A systematic Review. J Clin Gastroenterol 2013; 47 (10) 824-827
259 Al-Taie O, Al-Taie E, Fischbach W. Patients with Helicobacter pylori negative gastric marginal zone B-cell lymphoma (MZBCL) of MALT have a good prognosis. Z Gastroenterol 2014; 52: 1389-1393
260 Fischbach W, Goebeler ME, Ruskone-Fourmestraux A. et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be safely managed by a watch-and-wait strategy. Experience from a large international series. Gut 2007; 56: 1685-1687
261 Fischbach W, Dorlöchter C. Patients with gastric MALT lymphoma revealing persisting endoscopic abnormalities after successful eradication of Helicobacter pylori can be safely managed by a watch-and-wit strategy. Z Gastroenterol 2019; 57: 593-599
262 Ferreri AJM, Gove S, Ponzoni M. The role of Helicobacter pylori eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach. Curr Opin Oncol 2013; 25 (05) 470-479
263 Moayyedi P, Deeks J, Talley NJ. et al. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98: 2621-2626
264 Kang SJ, Park B, Shin CM. Helicobacter pylori Eradication Therapy for Functional Dyspepsia: A Meta-Analysis by Region and H. pylori Prevalence. J Clin Med 2019; 8 (09) 1324
265 Zhao B, Zhao J, Cheng WF. et al. Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia. A meta-analysis of randomized controlled studies with 12-month follow-up. J Clin Gastroenterol 2014; 48 (03) 241-247
266 Xu S, Wan X, Zheng X. et al. Symptom improvement after helicobacter pylori eradication in patients with functional dyspepsia – a multicenter, randomized, prospective cohort study. Int J Clin Exp Med 2013; 6 (09) 747-756
267 Zhao W, Zhong X, Zhuang X. et al. Evaluation of Helicobacter pylori eradication and drug therapy in patients with functional dyspepsia. Exp Ther Med 2013; 6 (01) 37-44
268 Kim SEK, Park YS, Kim N. et al. Effect of Helicobacter pylori eradication on functional dyspepsia. J Neurogastroenterol Motil 2013; 19 (02) 233-243
269 Sodhi JS, Javid G, Zargar SA. et al. Prevalence of Helicobacter pylori infection and the effect of ist eradication on symptoms of functional dyspepsia in Kashmir, India. J Gastroenterol Hepatol 2013; 28 (05) 808-813
270 Lan L, Yu J, Chen YL. et al. Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia. World J Gastroenterol 2011; 17: 3242-3247
271 Mazzoleni LE, Sander GB, Francesconi CF. et al. Helicobacter pylori Eradication in Functional Dyspepsia. HEROES Trial. Arch Intern Med 2011; 171 (21) 1929-1936
272 Koletzko L, Macke L, Schulz C. et al. Helicobacter pylori eradication in dyspepsia: New evidence for symptomatic benefit. Best Pract Res Clin Gastroenterol 2019; 40-41: 101637
273 Ford AC, Moayyedi P, Black CJ. et al. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Aliment Pharmacol Ther 2021; 53 (01) 8-21
274 Harvey RF, Lane JA, Nair P. et al. Clinical trial: prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations – the Bristol helicobacter Project. Aliment Pharmacol Ther 2010; 32: 394-400
275 Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol 2013; 10: 168-174
276 Cullen D, Hawkey G, Greenwood D. et al. H. pylori and gastroesophageal reflux disease: a community-based study. Helicobacter 2008; 13: 352-360
277 Nam SY, Choi IJ, Ryu KH. et al. Effect of Helicobacter pylori Infection and its Eradication on Reflux Esophagitis and Reflux Symptoms. Am J Gastroenterol 2010; 105: 2153-2162
278 Ashktorab H, Entezari O, Nouraie M. et al. Helicobacter pylori protection against reflux esophagitis. Dig Dis Sci 2012; 57: 2924-2928
279 Xie T, Cui X, Zheng H. et al. Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 2013; 25: 1195-1205
280 Rokkas T, Pistiolas D, Sechopoulos P. et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1413-1417
281 Wang C. et al. Helicobacter pylori Infection and Barrett’s Esophagus: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2009; 104: 492-500
282 Yaghoobi M, Farrokhyar F, Yuan Y. et al. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol 2010; 105: 1007-1013
283 Qian B, Shijie M, Shang L. et al. Effect of H. pylori eradication on gastroesophageal reflux disease. Helicobacter 2011; 121: 1120-1126
284 Rodriguez L, Faria CM, Geocze S. et al. Helicobacter pylori Eradication does not influence Gastroeosphageal Reflux Disease: a prospective, parallel, randomized, open-label, controlled trial. Arq Gastroenterol 2012; 49 (01) 56-63
285 Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesopha-geal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol 2012; 47: 129-135
286 Hirata K, Suzuki H, Matsuzaki J. et al. Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy. J Clin Biochem Nutr 2013; 52: 172-178
287 Wang XT, Zhang M, Chen CY. et al. Helicobacter pylori eradication and gastroesophageal reflux disease: a Meta-analysis. Zhonghua Nei Ke Za Zhi 2016; 55 (09) 710-716
288 Mitsushige S, Masaki M, Hitomi M. et al. Endoscopic Reflux Esophagitis and Reflux-Related Symptoms after Helicobacter pylori Eradication Therapy: Meta-Analysis. J. Clin. Med 2020; 9: 3007
289 Zhao Y, Li Y, Hu J. et al. The Effect of Helicobacter pylori Eradication in Patients with Gastroesophageal Reflux Disease: A Meta-Analysis of Randomized Controlled Studies. Dig Dis 2020; 38: 261-268
290 Kuipers EJ, Uyterlinde AM, Pena AS. et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90 (09) 1401-1406
291 Kuipers EJ, Lundell L, Klinkenberg-Knol EC. et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Eng J Med 1996; 334 (16) 1018-1022
292 Lundell L, Havu N, Miettinen P. et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006; 23 (05) 639-647
293 Hagiwara T, Mukaisho KI, Nakayama T. et al. Long-term proton pump inhibitor administration worsens atrophic gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut 2011; 60 (05) 624-630
294 Song H, Zhu J, Lu DH. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev 2014; (12) CD010623
295 Tran-Duy A, Spaetgens B, Hoes AW. et al. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2016; 14 (12) 1706-1719
296 Sanduleanu S, Jonkers D, De Bruine A. et al. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther 2001; 15 (08) 1163-1175
297 Sanduleanu S, Jonkers D, De Bruine A. et al. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther 2001; 15 (03) 379-388
298 Mukaisho KI, Hagiwara T, Nakayama T. et al. Potential mechanism of corpus-predominant gastritis after PPI therapy in Helicobacter pylori-positive patients with GERD. World J Gastroenterol 2014; 20 (34) 11962-11965
299 Lundell L, Vieth M, Gibson F. et al. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015; 42 (06) 649-663
300 Cheung KS, Chan EW, Wong AYS. et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut 2018; 67: 28-35
301 Jiang K, Jing X, Wen Y. et al. Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis. J Gastroenterol Hepatol 2019; 34 (11) 1898-1905
302 Seo SI, Park CH, You SCV. et al. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut 2021; 70 (11) 2066-2075
303 Arnold DM, Bernotas A, Nazi I. et al. Platelet count response to H pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica 2009; 94: 850-856
304 Stasi R, Sarpatwari A, Segal JB. et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: A systematic review. Blood 2009; 113: 1231-1240
305 Kim BJ, Kim HS, Jang HJ. et al. Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials. Gastroenterology Research and Practice 2018; 2018: 6090878
306 Madisch A, Miehlke S, Neuber F. et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy – a randomized, double-blind, placebo-controlled multicentre trial. Aliment Pharmacol Ther 2006; 23 (04) 473-479
307 Joo M. Rare Gastric Lesions Associated with Helicobacter pylori Infection: A Histopathological Review. J Pathol Med 2017; 51 (04) 341-551
308 Yoshimura M, Hirai M, Tanaka N. et al. Remission of severe anemia persisting for over 20 years after eradication of Helicobacter pylori in cases of Menetrier’s disease and atrophic gastritis: Helicobacter pylori as a pathogenic factor in iron-deficiency anemia. Intern Med 2003; 42 (10) 971-977
309 Kawasaki M, Hizawa K, Aoyagi K. et al. Menetrier’s disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. Am J Gastroenterol 1997; 92 (10) 1909-1912
310 Yamada M, Sumazaki R, Adachi H. et al. Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori. Eur J Pediatr 1997; 156 (03) 182-185
311 Bayerdörffer E, Ritter MM, Hatz R. et al. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori--is Helicobacter pylori a pathogenic factor in Menetrier’s disease?. Gut 1994; 35 (05) 701-704
312 Madsen LG, Taskiran M, Madsen JL. et al. Menetrier’s disease and Helicobacter pylori. Normalization of Gastrointestinal Protein Loss after Eradication therapy. Dig Dis Sci 1999; 44 (11) 2307-2312
313 Badov D, Lambert JR, Finlay M. et al. Helicobacter pylori as a pathogenetic factor in Menetrier’s disease. Am J Gastroenterol 1998; 93 (10) 1976-1979
314 Huh WJ, Coffey RJ, Washington MK. Menetrier’s Disease: Its Mimickers and Pathogenesis. J Pathol Transl Med 2016; 50 (01) 10-16
315 Chen Q, Zhou X, Tan W. et al. Association between Helicobacter pylori infection and Sjögren syndrome: A meta-analysis. Medicine (Baltimore) 2018; 97 (49) e13528
316 Saghafi M, Abdolahi N, Orang R. et al. Helicobacter Pylori Infection in Sjogren’s Syndrome: Co-incidence or Causality?. Curr Rheumatol Rev 2019; 15 (03) 238-241
317 Prelipcean CC, Mihai C, Gogalniceanu C. et al. Extragastric manifestations of Helicobacter pylori infection. Rev Med Chir Soc Med Nat Iasi 2007; 111 (03) 575-583
318 Gasbarrini A, Franceschi F. Autoimmune diseases and Helicobacter pylori infection. Biomed Pharmacother 1999; 53 (05) 223-226
319 Bartoloni E, Alunno A, Gerli R. The dark side of Sjogren’s syndrome: the possible pathogenic role of infections. Curr Opin Rheumatol 2019; 31 (05) 505-511
320 Xiong L-J, Tong Y, Wang Z-L. et al. Is Helicobacter pylori infection associated with Henoch-Schonlein purpura in Chinese children? A meta-analysis. World J Pediatr 2012; 8: 301-308
321 Xiong L-J, Mao M. Current views of the relationship between Helicobacter pylori and Henoch-Schonlein purpura in children. World J Clin Pediatr 2016; 5: 82-88
322 Hudak L, Jaraisy A, Haj S. et al. An updated systematic review and meta-analysis on the association between Helicobacter pylori infection and iron deficiency anemia. Helicobacter 2017; 22 (01)
323 Qu XH, Huang XL, Xiong P. et al. Does Helicobacter pylori infection play a role in iron deficiency anemia?. World J Gastroenterol 2010; 16: 886-896
324 Queiroz DMM, Harris PR, Sanderson IR. et al. Iron Status and Helicobacter pylori infection in symptomatic children: An international Multicentered study. PLOS One 2013; 8 (07) e68833
325 Duque X, Moran S, Mera R. et al. Effect of eradication of Helicobacter pylori and iron supplementation on the iron status of children with iron deficiency. Arch Med Res 2010; 41 (01) 38-45
326 Herter-Aeberli I, Eliancy K, Rathon Y. et al. In Haitian women and preschool children, iron absorption from wheat flour-based meals fortified with sodium iron EDTA is higher than that from meals fortified with ferrous fumarate, and is not affected by Helicobacter pylori infection in children. Br J Nutr 2017; 118 (04) 273-279
327 Venerito M, Schneider C, Costanzo R. et al. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment Pharmacol Ther 2018; 47 (11) 1464-1471
328 Sarri GL, Grigg SE, Yeomans ND. Helicobacter pylori and low-dose aspirin ulcer risk: A meta-analysis. J Gastroenterol Hepatol 2019; 34 (03) 517-525
329 Chan FK, To KF, Wu JC. et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13
330 Tang CL, Ye F, Liu W. et al. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis. Helicobacter 2012; 17 (04) 286-296
331 Lai KC, Lam SK, Chu KM. et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users – a randomized trial. Aliment Pharmacol Ther 2003; 18: 829-836
332 Hawkey CJ, Tulassay Z, Szczepanski L. et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352: 1016-1021
333 de Leest HT, Steen KS, Lems WF. et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 2007; 12: 477-485
334 Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. 2013 Available from: https://www.ncbi.nlm.nih.gov/books/NBK154370
335 Venerito M, Schneider C, Costanzo R. et al. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment Pharmacol Ther 2018; 47 (11) 1464-1471
336 Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol 2017; 23 (11) 1954-1963
337 Lauffenburger JC, Rhoney DH, Farley JF. et al. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. Pharmacotherapy 2015; 35 (06) 560-568
338 Suceveanu AI, Suceveanu AP, Parepa I. et al. Reducing upper digestive bleeding risk in patients treated with direct oral anticoagulants and concomitant infection with Helicobacter pylori. Exp Ther Med 2020; 20 (06) 205
339 Dall M, Schaffalitzky de Muckadell OB, Moller Hansen J. et al. Helicobacter pylori and risk of upper gastrointestinal bleeding among users of selective serotonin reuptake inhibitors. Scand J Gastroenterol 2011; 46: 1039-1044
340 Guo CG, Cheung KS, Zhang F. et al. Risks of hospitalization for upper gastrointestinal bleeding in users of selective serotonin reuptake inhibitors after Helicobacter pylori eradication therapy: a propensity score matching analysis. Aliment Pharmacol Ther 2019; 50: 1001-1008
341 Chan FKL, Chung SC, Suen BY. et al. Preventing Recurrent Upper Gastrointestinal Bleeding in Patients with Helicobacter pylori Infection who are taking Low-Dose Aspirin or Naproxen. N Engl J Med 2001; 344: 967-973
342 Chan FKL, Ching JYL, Suen BY. et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144: 528-553
343 Group I.H.p.W. Helicobacter pylori eradication as a strategy for preventing gastric cancer. IARC Working Group Reports Volume 8. 2014. ISBN-13; 978-92-832-2454-9
344 Wang C, Yuan Y, Hunt RH. The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am J Gastroenterol 2007; 102 (08) 1789-1798
345 Derks S, Bass AJ. Mutational signatures in Helicobacter pylori-induced gastric cancer: lessons from new sequencing technologies. Gastroenterology 2014; 147 (02) 267-269
346 Shimizu T. et al. Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection. Gastroenterology 2014; 147 (02) 07-17.e3
347 Stoicov C. et al. Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling. Gene 2004; 341: 1-17
348 Kodaman N. et al. Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proc Natl Acad Sci U S A 2014; 111 (04) 1455-1460
349 Bornschein J. et al. Molecular diagnostics in gastric cancer. Front Biosci (Landmark Ed) 2014; 19: 312-338
350 Ekström AM. et al. Occupational exposures and risk of gastric cancer in a population-based case-control study. Cancer Res 1999; 59 (23) 5932-5937
351 Miehlke S. et al. The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. Int J Cancer 2000; 87 (03) 322-327
352 Basso D. et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 2008; 135 (01) 91-99
353 Jang S. et al. Epidemiological link between gastric disease and polymorphisms in VacA and CagA. J Clin Microbiol 2010; 48 (02) 559-567
354 Rizzato C. et al. Variations in Helicobacter pylori cytotoxin-associated genes and their influence in progression to gastric cancer: implications for prevention. PLoS One 2012; 7 (01) e29605
355 Ekström AM. et al. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. Int J Cancer 2000; 87 (01) 133-140
356 González CA. et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98 (05) 345-354
357 González CA, López-Carrillo L. Helicobacter pylori, nutrition and smoking interactions: their impact in gastric carcinogenesis. Scand J Gastroenterol 2010; 45 (01) 6-14
358 Plummer M. et al. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 2015; 136 (02) 487-490
359 Liou JM. et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut 2020; 69 (12) 2093-2112
360 Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85 (11) 1457-1459
361 Bornschein J. et al. H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci 2010; 55 (11) 3124-3131
362 Cavaleiro-Pinto M. et al. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control 2011; 22 (03) 375-387
363 Derakhshan MH. et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 2008; 57 (03) 298-305
364 Hansen S. et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007; 56 (07) 918-925
365 Peleteiro B. et al. Is cardia cancer aetiologically different from distal stomach cancer?. Eur J Cancer Prev 2011; 20 (02) 96-101
366 McColl KE, Watabe H, Derakhshan MH. Role of gastric atrophy in mediating negative association between Helicobacter pylori infection and reflux oesophagitis, Barrett’s oesophagus and oesophageal adenocarcinoma. Gut 2008; 57 (06) 721-723
367 Bornschein J. et al. Adenocarcinomas at different positions at the gastro-oesophageal junction show distinct association with gastritis and gastric preneoplastic conditions. Eur J Gastroenterol Hepatol 2015; 27 (05) 492-500
368 Rice TW. et al. Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer. J Thorac Oncol 2017; 12 (01) 36-42
369 Arnold M, Park JY, Camargo MC. et al. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut 2020; 69 (05)
370 Hooi JKY. et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153 (02) 420-429
371 Franck C, Hoffmann A, Link A. et al. Prevalence of Helicobacter pylori infection among blood donors in Saxony-Anhalt, Germany – a region at intermediate risk for gastric cancer. Z Gastroenterol 2017; 55 (07) 653-656
372 Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut 2020; 69 (12) 2113-2121
373 Doorakkers E, Lagergren J, Engstrand L. et al. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut 2018; 67 (12) 2092-2096
374 Chiang TH. et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut 2021; 70 (02) 243-250
375 Lansdorp-Vogelaar I, Sharp L. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract Res Clin Gastroenterol 2013; 27 (06) 933-947
376 Chen Q. et al. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter 2019; 24 (02) e12563
377 Lansdorp-Vogelaar I, Meester RGS, Laszkowska M. et al. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. Best Pract Res Clin Gastroenterol 2021; 50-51: 101735
378 Selgrad M. et al. Combined Gastric and Colorectal Cancer Screening – A New Strategy. Int J Mol Sci 2018; 19 (12)
379 Areia M. et al. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk. United European Gastroenterol J 2018; 6 (02) 192-202
380 Leung WK. et al. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology 2018; 155 (01) 67-75
381 di Mario F, Cavallaro LG. Non-invasive tests in gastric diseases. Dig Liver Dis 2008; 40 (07) 523-530
382 Leja M. et al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci 2009; 54 (11) 2377-2384
383 Kitahara F. et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999; 44 (05) 693-697
384 Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006; 9 (04) 245-253
385 Watabe H. et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54 (06) 764-768
386 Yoshihara M. et al. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study. Scand J Gastroenterol 2007; 42 (06) 760-764
387 Terasawa T. et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS One 2014; 9 (10) e109783
388 Oishi Y. et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006; 163 (07) 629-637
389 Yanaoka K. et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008; 17 (04) 838-845
390 Zhang X. et al. Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community. Int J Cancer 2012; 130 (07) 1614-1619
391 Lomba-Viana R. et al. Serum pepsinogen test for early detection of gastric cancer in a European country. Eur J Gastroenterol Hepatol 2012; 24 (01) 37-41
392 Moehler M. et al. S3-Leitlinie Magenkarzinom. Z Gastroenterol 2019; 57 (12) 1517-1632
393 Huang YK. et al. Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. PLoS One 2015; 10 (11) e0142080
394 Gupta S. et al. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology 2020; 158 (03) 693-702
395 Hamashima C. Update version of the Japanese Guidelines for Gastric Cancer Screening. Jpn J Clin Oncol 2018; 48 (07) 673-683
396 Zagari RM. et al. Prevalence of upper gastrointestinal endoscopic findings in the community: A systematic review of studies in unselected samples of subjects. J Gastroenterol Hepatol 2016; 31 (09) 1527-1538
397 Bang CS, Lee JJ, Baik GH. Prediction of Chronic Atrophic Gastritis and Gastric Neoplasms by Serum Pepsinogen Assay: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy. J Clin Med 2019; 8 (05)
398 Song M. et al. Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males. Aliment Pharmacol Ther 2018; 47 (04) 494-503
399 El-Omar EM. et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology 2000; 118 (01) 22-30
400 Oh S. et al. Risk factors of atrophic gastritis and intestinal metaplasia in first-degree relatives of gastric cancer patients compared with age-sex matched controls. J Cancer Prev 2013; 18 (02) 149-160
401 Choi IJ. et al. Family History of Gastric Cancer and Helicobacter pylori Treatment. N Engl J Med 2020; 382 (05) 427-436
402 Venerito M, Vasapolli R, Malfertheiner P. Helicobacter pylori and Gastric Cancer: Timing and Impact of Preventive Measures. Adv Exp Med Biol 2016; 908: 409-418
403 Panteris V. et al. Diagnostic capabilities of high-definition white light endoscopy for the diagnosis of gastric intestinal metaplasia and correlation with histologic and clinical data. Eur J Gastroenterol Hepatol 2014; 26 (06) 594-601
404 Pimentel-Nunes P. et al. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. Endoscopy 2016; 48 (08) 723-730
405 Ang TL. et al. A multicenter randomized comparison between high-definition white light endoscopy and narrow band imaging for detection of gastric lesions. Eur J Gastroenterol Hepatol 2015; 27 (12) 1473-1478
406 Kim YI. et al. Effect of biopsy site on detection of gastric cancer high-risk groups by OLGA and OLGIM stages. Helicobacter 2017; 22 (06)
407 Isajevs S. et al. The effect of incisura angularis biopsy sampling on the assessment of gastritis stage. Eur J Gastroenterol Hepatol 2014; 26 (05) 510-513
408 Varbanova M, Wex T, Jechorek D. et al. Impact of the angulus biopsy for the detection of gastric preneoplastic conditions and gastric cancer risk assessment. J Clin Pathol 2016; 69 (01) 19-25
409 Arnold M. et al. The burden of stomach cancer in indigenous populations: a systematic review and global assessment. Gut 2014; 63 (01) 64-71
410 De Vries AC. et al. Migrant communities constitute a possible target population for primary prevention of Helicobacter pylori-related complications in low incidence countries. Scand J Gastroenterol 2008; 43 (04) 403-409
411 Saumoy M. et al. Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity. Gastroenterology 2018; 155 (03) 648-660
412 Murphy G. et al. Cancer Risk After Pernicious Anemia in the US Elderly Population. Clin Gastroenterol Hepatol 2015; 13 (13) 2282-2289. e1-4
413 Weise F, Vieth M, Reinhold D. et al. Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research. United European Gastroenterol J 2020; 8 (02) 175-184
414 Wong BC. et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291 (02) 187-194
415 Rugge M, Genta RM. Staging gastritis: an international proposal. Gastroenterology 2005; 129 (05) 1807-1808
416 Rugge M. et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56 (05) 631-636
417 Capelle LG. et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010; 71 (07) 1150-1158
418 Rugge M. et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut 2019; 68 (01) 11-17
419 Isajevs S. et al. Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems. Virchows Arch 2014; 464 (04) 403-407
420 Leja M. et al. Interobserver variation in assessment of gastric premalignant lesions: higher agreement for intestinal metaplasia than for atrophy. Eur J Gastroenterol Hepatol 2013; 25 (06) 694-699
421 Marcos-Pinto R. et al. First-degree relatives of patients with early-onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/OLGIM stages and dysplasia. Aliment Pharmacol Ther 2012; 35 (12) 1451-1459
422 Rugge M. et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010; 31 (10) 1104-1111
423 Take S. et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol 2011; 46 (03) 318-324
424 Yanaoka K. et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer 2009; 125 (11) 2697-2703
425 Kodama M. et al. Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol 2013; 48 (11) 1249-1256
426 Rokkas T. et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007; 12 (Suppl. 02) 32-38
427 Yoshida T. et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. Int J Cancer 2014; 134 (06) 1445-1457
428 Areia M, Dinis-Ribeiro M, Rocha Gonçalves F. Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions. Helicobacter 2014; 19 (06) 425-436
429 Rugge M, Genta RM, Fassan M. et al. OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. Am J Gastroenterol 2018; 113 (11) 1621-1628
430 Kato M. et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut 2013; 62 (10) 1425-1432
431 Pimentel-Nunes P. et al. Long-term follow-up after endoscopic resection of gastric superficial neoplastic lesions in Portugal. Endoscopy 2014; 46 (11) 933-940
432 Fukase K. et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-397
433 Choi JM. et al. Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial. Gastrointest Endosc 2018; 88 (03) 475-485.e2
434 Choi Y, Kim N, Yoon H. et al. The Incidence and Risk Factors for Metachronous Gastric Cancer in the Remnant Stomach after Gastric Cancer Surgery. Gut Liver 2021;
435 Choi IJ. et al. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med 2018; 378 (12) 1085-1095
436 Malfertheiner P. Helicobacter pylori Treatment for Gastric Cancer Prevention. N Engl J Med 2018; 378 (12) 1154-1156
437 Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 2007; 132 (07) 2320-2327
438 Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol 2007; 102 (05) 1101-1107
439 Malfertheiner P, Schulz C. Peptic Ulcer: Chapter Closed?. Dig Dis 2020; 1-5
440 Van der Hulst RW. et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology 1997; 113 (04) 1082-1086
441 Venerito M, Schneider C, Costanzo R. et al. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment Pharmacol Ther 2018; 47 (11) 1464-1471
442 Hellström PM, Benno P, Malfertheiner P. Gastrointestinal bleeding in patients with Helicobacter pylori and dual platelet inhibition after myocardial infarction. Lancet Gastroenterol Hepatol 2021; 6 (09) 684-685
443 Gisbert JP. et al. Eradication of Helicobacter pylori for the prevention of peptic ulcer rebleeding. Helicobacter 2007; 12 (04) 279-278
444 Wong CS. et al. Eradication of Helicobacter pylori for prevention of ulcer recurrence after simple closure of perforated peptic ulcer: a meta-analysis of randomized controlled trials. J Surg Res 2013; 182 (02) 219-226
445 Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26 (03) 343-357
446 Malfertheiner P, Selgrad M. Helicobacter pylori. Curr Opin Gastroenterol 2014; 30 (06) 589-595
447 Selgrad M, Meissle J, Bornschein J. et al. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Eur J Gastroenterol Hepatol 2013; 25 (11) 1257-1260
448 Megraud F, Coenen S, Versporten A. et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62 (01) 34-42
449 Wüppenhorst N, Draeger S, Stüger HP. et al. Prospective multicentre study on antimicrobial resistance of Helicobacter pylori in Germany. J Antimicrob Chemother 2014; 69 (11) 3127-3133
450 Savoldi A, Carrara E, Graham DY. et al. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155 (05) 1372-1382.e17
451 Megraud F, Bruyndonckx R, Coenen S. et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and ist relationship to antibiotic consumption in the community. Gut 2021; 70: 1815-1822
452 Bluemel B, Goelz H, Goldmann B. et al. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018. Clin Microbiol Infect 2020; 26 (02) 235-239
453 Kuo C-H, Lu C-Y, Shih H-Y. et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol 2014; 20 (43) 16029-16036
454 Nyssen OP, Perez-Aisa A, Castro-Fernandez M. et al. European Registry on Helicobacter pylori Management: single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United Eur Gastroenterol J 2020;
455 Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter 2019; 24 (02) e12570
456 Nyssen OP, Perez-Aisa A, Castro-Fernandez M. et al. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United Eur Gastroenterol J 2021; 9 (01) 38-46
457 Lee HJ, Kim JIl, Cheung DY. et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis 2013; 208 (07) 1123-1130
458 Cho J-H, Jeon SR, Kim HG. et al. Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients. J Gastroenterol Hepatol 2019; 34 (04) 700-706
459 Amini M, Tajik A. Oral and intravenous eradication of Helicobacter pylori. Pakistan J Biol Sci PJBS 2009; 12 (10) 809-812
460 Schilling D, Demel A, Nüsse T. et al. Helicobacter pylori infection does not affect the early rebleeding rate in patients with peptic ulcer bleeding after successful endoscopic hemostasis: a prospective single-center trial. Endoscopy 2003; 35 (05) 393-396
461 Selgrad M, Meyer F, Malfertheiner P. Helicobacter pylori: Kurzabriss zu ausgewählten historischen Etappen des Erkenntnisprozesses und ihre Bedeutung für die klinische Medizin, insbesondere auch die Chirurgie – was der (Allgemein-/Viszeral-)Chirurg wissen sollte. Zentralblatt für Chir – Zeitschrift für Allg Visz Thorax- und Gefäßchirurgie 2014; 139 (04) 399-405
462 Hu Y, Wan J-H, Li X-Y. et al. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther 2017; 46 (09) 773-779
463 Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol 2005; 100 (09) 2083-2099
464 Jones NL, Koletzko S, Goodman K. et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017; 64 (06) 991-1003
465 Harris PR, Calderon-Guerrero OG, Vera-Chamorro JF. et al. [Adaptation to the reality of Latin America of the NASPGHAN/ESPGHAN 2016 Guidelines on the Diagnosis, Prevention and Treatment of Helicobacter pylori Infection in Pediatrics]. Rev Chil Pediatr 2020; 91 (05) 809-827
466 Kato S, Shimizu T, Toyoda S. et al. The updated JSPGHAN guidelines for the management of Helicobacter pylori infection in childhood. Pediatr Int 2020; 62 (12) 1315-1331
467 Rowland M, Clyne M, Daly L. et al. Long-term follow-up of the incidence of Helicobacter pylori. Clin Microbiol Infect 2018; 24 (09) 980-984
468 Elias N, Nasrallah E, Khoury C. et al. Associations of Helicobacter pylori seropositivity and gastric inflammation with pediatric asthma. Pediatr Pulmonol 2020; 55 (09) 2236-2245
469 Fouda EM, Kamel TB, Nabih ES. et al. Helicobacter pylori seropositivity protects against childhood asthma and inversely correlates to its clinical and functional severity. Allergol Immunopathol (Madr) 2018; 46 (01) 76-81
470 Lim JH, Kim N, Lim SH. et al. Inverse Relationship Between Helicobacter Pylori Infection and Asthma Among Adults Younger than 40 Years: A Cross-Sectional Study. Medicine (Baltimore) 2016; 95 (08) e2609
471 Taye B, Enquselassie F, Tsegaye A. et al. Is Helicobacter Pylori infection inversely associated with atopy? A systematic review and meta-analysis. Clin Exp Allergy 2015; 45 (05) 882-890
472 Chen Y, Zhan X, Wang D. Association between Helicobacter pylori and risk of childhood asthma: a meta-analysis of 18 observational studies. J Asthma 2021; 1-17
473 Imawana RA, Smith DR, Goodson ML. The relationship between inflammatory bowel disease and Helicobacter pylori across East Asian, European and Mediterranean countries: a meta-analysis. Ann Gastroenterol 2020; 33 (05) 485-494
474 Sayar R, Shokri Shirvani J, Hajian-Tilaki K. et al. The negative association between inflammatory bowel disease and Helicobacter pylori seropositivity. Caspian J Intern Med 2019; 10 (02) 217-222
475 Kori M, Le Thi TG, Werkstetter K. et al. Helicobacter pylori Infection in Pediatric Patients Living in Europe: Results of the EuroPedHP Registry 2013 to 2016. J Pediatr Gastroenterol Nutr 2020; 71 (04) 476-483
476 Okuda M, Nomura K, Kato M. et al. Gastric cancer in children and adolescents in Japan. Pediatr Int 2019; 61 (01) 80-86
477 Schwille IJ, Giel KE, Ellert U. et al. A community-based survey of abdominal pain prevalence, characteristics, and health care use among children. Clin Gastroenterol Hepatol 2009; 7 (10) 1062-1068
478 Gulewitsch MD, Enck P, Schwille-Kiuntke J. et al. Rome III criteria in parents’ hands: pain-related functional gastrointestinal disorders in community children and associations with somatic complaints and mental health. Eur J Gastroenterol Hepatol 2013; 25 (10) 1223-1229
479 Chitkara DK, Rawat DJ, Talley NJ. The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic review. Am J Gastroenterol 2005; 100 (08) 1868-1875
480 Chobot A, Porebska J, Krzywicka A. et al. No association between Helicobacter pylori infection and gastrointestinal complaints in a large cohort of symptomatic children. Acta Paediatr 2019; 108 (08) 1535-1540
481 Correa Silva RG, Machado NC, Carvalho MA. et al. Helicobacter pylori infection is high in paediatric nonulcer dyspepsia but not associated with specific gastrointestinal symptoms. Acta Paediatr 2016; 105 (05) e228-e231
482 Rejchrt S, Koupil I, Kopacova M. et al. The prevalence and sociodemographic determinants of uninvestigated dyspepsia in the Czech Republic: a multicentre prospective study accomplished 10 years after the first study from the same geographical areas. Eur J Gastroenterol Hepatol 2018; 30 (01) 76-82
483 Kim BJ, Kim HS, Jang HJ. et al. Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials. Gastroenterol Res Pract 2018; 2018: 6090878
484 Sheema K, Ikramdin U, Arshi N. et al. Role of Helicobacter pylori Eradication Therapy on Platelet Recovery in Chronic Immune Thrombocytopenic Purpura. Gastroenterol Res Pract 2017; 2017: 9529752
485 Abdollahi A, Shoar S, Ghasemi S. et al. Is Helicobacter pylori infection a risk factor for idiopathic thrombocytopenic purpura in children?. Ann Afr Med 2015; 14 (04) 177-181
486 Brito HS, Braga JA, Loggetto SR. et al. Helicobacter pylori infection & immune thrombocytopenic purpura in children and adolescents: A randomized controlled trial. Platelets 2015; 26 (04) 336-341
487 Wang JJ, Xu Y, Liu FF. et al. Association of the infectious triggers with childhood Henoch-Schonlein purpura in Anhui province, China. J Infect Public Health 2020; 13 (01) 110-117
488 Xiong LJ, Mao M. Current views of the relationship between Helicobacter pylori and Henoch-Schonlein purpura in children. World J Clin Pediatr 2016; 5 (01) 82-88
489 Cornillier H, Giraudeau B, Munck S. et al. Chronic spontaneous urticaria in children – a systematic review on interventions and comorbidities. Pediatr Allergy Immunol 2018; 29 (03) 303-310
490 Kudryavtseva AV, Neskorodova KA, Staubach P. Urticaria in children and adolescents: An updated review of the pathogenesis and management. Pediatr Allergy Immunol 2019; 30 (01) 17-24
491 Williams PV. Pharmacologic Management of Chronic Urticaria in Pediatric Patients: The Gap Between Guidelines and Practice. Paediatr Drugs 2020; 22 (01) 21-28
492 Akelma AZ, Cizmeci MN, Mete E. et al. A neglected cause for chronic spontaneous urticaria in children: Helicobacter pylori. Allergol Immunopathol (Madr) 2015; 43 (03) 259-263
493 Zahmatkeshan M, Karimi M, Geramizadeh B. et al. Association between Helicobacter pylori Infection and Iron Deficiency Anemia in School-aged Iranian Children. Indian Pediatr 2019; 56 (05) 387-389
494 Gheibi S, Farrokh-Eslamlou HR, Noroozi M. et al. Refractory iron deficiency anemia and Helicobacter Pylori Infection in pediatrics: A review. Iran J Ped Hematol Oncol 2015; 5 (01) 50-64
495 Mendoza E, Duque X, Hernandez Franco JI. et al. Association between Active H. pylori Infection and Iron Deficiency Assessed by Serum Hepcidin Levels in School-Age Children. Nutrients 2019; 11 (09)
496 Buerkli S, Fatou Ndiaye N, Cercamondi CI. et al. Asymptomatic Helicobacter Pylori Infection in Preschool Children and Young Women Does Not Predict Iron Bioavailability from Iron-Fortified Foods. Nutrients 2019; 11 (09)
497 Burgard M, Kotilea K, Mekhael J. et al. Evolution of Helicobacter pylori associated with gastroduodenal ulcers or erosions in children over the past 23 years: Decline or steady state?. Helicobacter 2019; 24 (05) e12629
498 Alper A, Hardee S, Rojas-Velasquez D. et al. Prevalence and Clinical, Endoscopic, and Pathological Features of Duodenitis in Children. J Pediatr Gastroenterol Nutr 2016; 62 (02) 314-316
499 Ganga-Zandzou PS, Michaud L, Vincent P. et al. Natural outcome of Helicobacter pylori infection in asymptomatic children: a two-year follow-up study. Pediatrics 1999; 104 (02) 216-221
500 Lazowska-Przeorek I, Kotowska M, Banasiuk M. et al. Value of Antral Nodularity for the Diagnosis of Helicobacter pylori Infection in Children. Med Sci Monit 2015; 21: 1827-1830
501 Koletzko S, Richy F, Bontems P. et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006; 55 (12) 1711-1716
502 El-Shabrawi M, El-Aziz NA, El-Adly TZ. et al. Stool antigen detection versus (13)C-urea breath test for non-invasive diagnosis of pediatric Helicobacter pylori infection in a limited resource setting. Arch Med Sci 2018; 14 (01) 69-73
503 Calik Z, Karamese M, Acar O. et al. Investigation of Helicobacter pylori antigen in stool samples of patients with upper gastrointestinal complaints. Braz J Microbiol 2016; 47 (01) 167-171
504 Kalach N, Gosset P, Dehecq E. et al. A one-step immune-chromatographic Helicobacter pylori stool antigen test for children was quick, consistent, reliable and specific. Acta Paediatr 2017; 106 (12) 2025-2030
505 Moubri M, Burucoa C, Kalach N. et al. Performances of the IDEIA HpStAR Stool Antigen Test in Detection of Helicobacter pylori Infection Before and After Eradication Treatment in Algerian Children. J Trop Pediatr 2019; 65 (03) 210-216
506 Beer-Davidson G, Hindiyeh M, Muhsen K. Detection of Helicobacter pylori in stool samples of young children using real-time polymerase chain reaction. Helicobacter 2018; 23 (01)
507 Kusano C, Gotoda T, Ikehara H. et al. The Accuracy of the Serum Antibody Test for Helicobacter pylori Infection among Junior High School Students. Digestion 2021; 102 (02) 155-160
508 Graham DY, Liou JM. Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship. Clin Gastroenterol Hepatol 2021;
509 Jansson L, Agardh D. Prevalence of clarithromycin-resistant Helicobacter pylori in children living in South of Sweden: a 12-year follow-up. Scand J Gastroenterol 2019; 54 (07) 838-842
510 Guven B, Gulerman F, Kacmaz B. Helicobacter pylori resistance to clarithromycin and fluoroquinolones in a pediatric population in Turkey: A cross-sectional study. Helicobacter 2019; 24 (03) e12581
511 Butenko T, Jeverica S, Orel R. et al. Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children. Helicobacter 2017; 22 (05)
512 Zhou Y, Ye Z, Wang Y. et al. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children. Helicobacter 2020; 25 (02) e12679
513 Lopo I, Libanio D, Pita I. et al. Helicobacter pylori antibiotic resistance in Portugal: Systematic review and meta-analysis. Helicobacter 2018; 23 (04) e12493
514 Tamayo E, Montes M, Fernandez-Reyes M. et al. Clarithromycin resistance in Helicobacter pylori and its molecular determinants in Northern Spain, 2013-2015. J Glob Antimicrob Resist 2017; 9: 43-46
515 Krzyzek P, Pawelka D, Iwanczak B. et al. High Primary Antibiotic Resistance of Helicobacter pylori Strains Isolated from Pediatric and Adult Patients in Poland during 2016–2018. Antibiotics (Basel) 2020; 9 (05)
516 Kori M, Yahav J, Berdinstein R. et al. Primary and Secondary Antibiotic Resistance of Helicobacter pylori in Israeli Children and Adolescents. Isr Med Assoc J 2017; 19 (12) 747-750
517 Miyata E, Kudo T, Ikuse T. et al. Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single-center study over 12 years. Helicobacter 2021; 26 (01) e12764
518 Lucero Y, George S, O’Ryan M. Indications for Helicobacter pylori Eradication: Do We Need to Consider to Screen and Treat Asymptomatic Children?. J Pediatr Gastroenterol Nutr 2018; 67 (04) e86-e87
519 Koletzko S, Jones N. No Screen and Treat in Children for Helicobacter pylori Infection. J Pediatr Gastroenterol Nutr 2018; 67 (04) e87-e88
520 Kotilea K, Kalach N, Homan M. et al. Helicobacter pylori Infection in Pediatric Patients: Update on Diagnosis and Eradication Strategies. Paediatr Drugs 2018; 20 (04) 337-351
521 Kori M, Daugule I, Urbonas V. Helicobacter pylori and some aspects of gut microbiota in children. Helicobacter 2018; 23 (Suppl. 01) e12524
522 Kaji E, Yoden A, Otani M. et al. Helicobacter pylori test-and-treat strategy for second-year junior high school students aimed at the prevention of gastric cancer in Takatsuki City. Helicobacter 2020; 25 (04) e12696
523 Huang Y, Zhan X. Sequential Therapy is Superior to Triple Therapy for Helicobacter pylori Infection in Children: A Meta-Analysis. Indian J Pediatr 2016; 83 (04) 307-315
524 Schwarzer A, Bontems P, Urruzuno P. et al. Sequential Therapy for Helicobacter pylori Infection in Treatment-naive Children. Helicobacter 2016; 21 (02) 106-113
525 Iwanczak BM, Borys-Iwanicka A, Biernat M. et al. Assessment of Sequential and Standard Triple Therapy in Treatment of Helicobacter pylori Infection in Children Dependent on Bacteria Sensitivity to Antibiotics. Adv Clin Exp Med 2016; 25 (04) 701-708
526 Dehghani SM, Nazari A, Javaherizadeh H. Effect of sequential therapy on treatment of Helicobacter pylori infection in children. Rev Gastroenterol Peru 2018; 38 (02) 128-130
527 Nyssen OP, McNicholl AG, Megraud F. et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016; 2016 (06) CD009034
528 Schwarzer A, Urruzuno P, Iwanczak B. et al. New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain. J Pediatr Gastroenterol Nutr 2011; 52 (04) 424-428
529 Zhou Y, Ye Z, Lu J. et al. Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children. Helicobacter 2020; 25 (05) e12721
530 Kotilea K, Mekhael J, Salame A. et al. Eradication rate of Helicobacter Pylori infection is directly influenced by adherence to therapy in children. Helicobacter 2017; 22 (04)
531 Feng JR, Wang F, Qiu X. et al. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol 2017; 73 (10) 1199-1208
532 Fang HR, Zhang GQ, Cheng JY. et al. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatr 2019; 178 (01) 7-16
533 Ahmad K, Fatemeh F, Mehri N. et al. Probiotics for the treatment of pediatric helicobacter pylori infection: a randomized double blind clinical trial. Iran J Pediatr 2013; 23 (01) 79-84
534 Szajewska H, Kolodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther 2015; 42 (10) 1149-1157
535 Akcam M, Koca T, Salman H. et al. The effects of probiotics on treatment of Helicobacter pylori eradication in children. Saudi Med J 2015; 36 (03) 286-290
536 Szajewska H, Horvath A, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015; 41 (12) 1237-1245
537 Lau CS, Ward A, Chamberlain RS. Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis. Infect Drug Resist 2016; 9: 275-289
538 Lu M, Yu S, Deng J. et al. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. PLoS One 2016; 11 (10) e0163743
539 Yu M, Zhang R, Ni P. et al. Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication: A meta-analysis of randomized controlled trials. PLoS One 2019; 14 (10) e0223309
540 Hassan ST, Sudomova M. Probiotics as Dietary Supplements for Eradication of Helicobacter pylori Infection in Children: A Role Beyond Infection. Children (Basel) 2016; 3 (04)
541 Castellsague J, Riera-Guardia N, Calingaert B. et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35 (12) 1127-1146
542 Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115 (10) 787-796
543 Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8 (01) 18-24
544 Henry D, Lim LL, Garcia Rodriguez LA. et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-1566
545 Campbell DR, Haber MM, Sheldon E. et al. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol 2002; 97 (09) 2208-2214
546 Graham DY, Agrawal NM, Campbell DR. et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162 (02) 169-175
547 Regula J, Butruk E, Dekkers CP. et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 2006; 101 (08) 1747-1755
548 Scheiman JM, Yeomans ND, Talley NJ. et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101 (04) 701-710
549 Joo MK, Park CH, Kim JS. et al. Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition. Gut Liver 2020; 14 (06) 707-726
550 Mo C, Sun G, Lu ML. et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol 2015; 21 (17) 5382-5392
551 Bang CS, Joo MK, Kim BW. et al. The Role of Acid Suppressants in the Prevention of Anticoagulant-Related Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. Gut Liver 2020; 14 (01) 57-66
552 Hunfeld NG, Touw DJ, Mathot RA. et al. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 2010; 31 (01) 150-159
553 Lanas A, Chan FKL. Peptic ulcer disease. Lancet 2017; 390: 613-624
554 Gonzalez-Perez A, Saez ME, Johansson S. et al. Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS One 2014; 9 (07) e101768
555 Garcia Rodriguez LA, Martin-Perez M, Hennekens CH. et al. Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PLoS One 2016; 11 (08) e0160046
556 Hawkey CJ, Weinstein WM, Smalley W. et al. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology 2007; 133 (01) 57-64
557 Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160 (14) 2093-2099
558 Lanas A, Carrera-Lasfuentes P, Arguedas Y. et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015; 13 (05) 906-912 e2
559 Lanas A, Wu P, Medin J. et al. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol 2011; 9 (09) 762-768 e6
560 Venerito M, Schneider C, Costanzo R. et al. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment Pharmacol Ther 2018; 47 (11) 1464-1471
561 Nagasue T, Nakamura S, Kochi S. et al. Time trends of the impact of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs on peptic ulcer bleeding in Japanese patients. Digestion 2015; 91 (01) 37-41
562 Cheung AN, Ng IO. Cytomegalovirus infection of the gastrointestinal tract in non-AIDS patients. Am J Gastroenterol 1993; 88 (11) 1882-1886
563 Dorigo-Zetsma JW, van der Meer JT, Tersmette M. et al. Value of laboratory investigations in clinical suspicion of cytomegalovirus-induced upper gastrointestinal tract ulcerations in HIV-infected patients. J Med Virol 1996; 49 (01) 29-33
564 Itami H, Morita K, Nakai T. et al. Gastritis cystica profunda is associated with aberrant p53 and Epstein-Barr virus in gastric cancer: A clinicopathological, immunohistochemical and in situ hybridization study. Pathol Int 2021; 71 (01) 42-50
565 Peter A, Telkes G, Varga M. et al. Endoscopic diagnosis of cytomegalovirus infection of upper gastrointestinal tract in solid organ transplant recipients: Hungarian single-center experience. Clin Transplant 2004; 18 (05) 580-584
566 Haanen J, Carbonnel F, Robert C. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl. 04) iv264-iv266
567 Kobayashi M, Yamaguchi O, Nagata K. et al. Acute hemorrhagic gastritis after nivolumab treatment. Gastrointest Endosc 2017; 86 (05) 915-916
568 Nishimura Y, Yasuda M, Ocho K. et al. Severe Gastritis after Administration of Nivolumab and Ipilimumab. Case Rep Oncol 2018; 11 (02) 549-556
569 Ricke J, Klumpen HJ, Amthauer H. et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 2019; 71 (06) 1164-1174
570 Shinoto M, Shioyama Y, Matsunobu A. et al. Dosimetric analysis of upper gastrointestinal ulcer after carbon-ion radiotherapy for pancreatic cancer. Radiother Oncol 2016; 120 (01) 140-144
571 Wasan HS, Gibbs P, Sharma NK. et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 2017; 18 (09) 1159-1171
572 Lanas A, Perez-Aisa MA, Feu F. et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100 (08) 1685-1693
573 Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 2013; 144 (07) 1384-1393 , 93 e1-2; quiz e18-9
574 Laine L, Bombardier C, Hawkey CJ. et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123 (04) 1006-1012
575 Weil J, Langman MJ, Wainwright P. et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46 (01) 27-31
576 Kanno T, Iijima K, Koike T. et al. Accommodation in a refugee shelter as a risk factor for peptic ulcer bleeding after the Great East Japan Earthquake: a case-control study of 329 patients. J Gastroenterol 2015; 50 (01) 31-40
577 Levenstein S, Rosenstock S, Jacobsen RK. et al. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol 2015; 13 (03) 498-506 e1
578 Yamanaka K, Miyatani H, Yoshida Y. et al. Hemorrhagic gastric and duodenal ulcers after the Great East Japan Earthquake Disaster. World J Gastroenterol 2013; 19 (42) 7426-7432
579 Lee SJ, Shin DH, Hwang HJ. et al. Bleeding risk and major adverse events in patients with previous ulcer on oral anticoagulation therapy. Am J Cardiol 2012; 110 (03) 373-377
580 Chan FK, Hung LC, Suen BY. et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004; 127 (04) 1038-1043
581 Abraham NS, Noseworthy PA, Inselman J. et al. Risk of Gastrointestinal Bleeding Increases With Combinations of Antithrombotic Agents and Patient Age. Clin Gastroenterol Hepatol 2020; 18 (02) 337-346 e19
582 Abraham NS, Noseworthy PA, Yao X. et al. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology 2017; 152 (05) 1014-1022 e1
583 Hsu YC, Lin JT, Chen TT. et al. Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: a 10-year nationwide cohort study. Hepatology 2012; 56 (02) 698-705
584 Kim M, Kim CS, Bae EH. et al. Risk factors for peptic ulcer disease in patients with end-stage renal disease receiving dialysis. Kidney Res Clin Pract 2019; 38 (01) 81-89
585 Luo JC, Leu HB, Hou MC. et al. Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study. Aliment Pharmacol Ther 2012; 36 (06) 542-550
586 Peng YL, Leu HB, Luo JC. et al. Diabetes is an independent risk factor for peptic ulcer bleeding: a nationwide population-based cohort study. J Gastroenterol Hepatol 2013; 28 (08) 1295-1299
587 Selak V, Jackson R, Poppe K. et al. Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis. Ann Intern Med 2019; 171 (08) 529-539
588 Siva R, Birring SS, Berry M. et al. Peptic ulceration, Helicobacter pylori seropositivity and chronic obstructive pulmonary disease. Respirology 2013; 18 (04) 728-731
589 Labenz J, Blum AL, Bolten WW. et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002; 51 (03) 329-335
590 Stupnicki T, Dietrich K, Gonzalez-Carro P. et al. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 2003; 68 (04) 198-208
591 Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol 2013; 48 (07) 830-838
592 Rostom A, Muir K, Dube C. et al. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf 2009; 1: 47-71
593 Scally B, Emberson JR, Spata E. et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018; 3 (04) 231-241
594 Wang X, Tian HJ, Yang HK. et al. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol 2011; 23 (10) 876-880
595 Chan FK, Wong VW, Suen BY. et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621-1626
596 Chan FKL, Ching JYL, Tse YK. et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet 2017; 389: 2375-2382
597 Cheetham TC, Levy G, Niu F. et al. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Ann Pharmacother 2009; 43 (11) 1765-1773
598 Masclee GM, Valkhoff VE, Coloma PM. et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 2014; 147 (04) 784-792
599 Tildesley G, Ehsanullah RS, Wood JR. Ranitidine in the treatment of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drugs. Br J Rheumatol 1993; 32 (06) 474-478
600 Chan FK, Chung SC, Suen BY. et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344 (13) 967-973
601 Sostres C, Carrera-Lasfuentes P, Benito R. et al. Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users. Am J Gastroenterol 2015; 110 (05) 684-689
602 Kelly JP, Kaufman DW, Jurgelon JM. et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413-1416
603 Slattery J, Warlow CP, Shorrock CJ. et al. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 37 (04) 509-511
604 Weil J, Colin-Jones D, Langman M. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-830
605 Yeomans ND, Lanas AI, Talley NJ. et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22 (09) 795-801
606 de Abajo FJ, Gil MJ, Bryant V. et al. Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database. Eur J Clin Pharmacol 2013; 69 (03) 691-701
607 Grove EL, Wurtz M, Schwarz P. et al. Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. J Gen Intern Med 2013; 28 (02) 216-222
608 Holster IL, Valkhoff VE, Kuipers EJ. et al. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013; 145 (01) 105-112 e15
609 Khan R, Lopes RD, Neely ML. et al. Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. Heart 2015; 101 (18) 1475-1484
610 Lopez-Lopez JA, Sterne JAC, Thom HHZ. et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017; 359: j5058
611 Ray WA, Chung CP, Murray KT. et al. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. JAMA 2018; 320 (21) 2221-2230
612 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962
613 Sherwood MW, Nessel CC, Hellkamp AS. et al. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. J Am Coll Cardiol 2015; 66 (21) 2271-2281
614 Lanas A, Fuentes J, Benito R. et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16 (04) 779-786
615 Lin KJ, Hernandez-Diaz S, Garcia Rodriguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology 2011; 141 (01) 71-79
616 Moayyedi P, Eikelboom JW, Bosch J. et al. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology 2019; 157 (02) 403-412 e5
617 Mo C, Sun G, Wang YZ. et al. PPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysis. PLoS One 2015; 10 (07) e0131558
618 Szabo IL, Matics R, Hegyi P. et al. PPIs Prevent Aspirin-Induced Gastrointestinal Bleeding Better than H2RAs. A Systematic Review and Meta-analysis. J Gastrointestin Liver Dis 2017; 26 (04) 395-402
619 Chan FK, Ching JY, Suen BY. et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144 (03) 528-535
620 Suceveanu AI, Suceveanu AP, Parepa I. et al. Reducing upper digestive bleeding risk in patients treated with direct oral anticoagulants and concomitant infection with Helicobacter pylori. Exp Ther Med 2020; 20 (06) 205
621 Scott MJ, Veitch A, Thachil J. Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when?. Br J Haematol 2017; 177 (02) 185-197
622 Schmidt M, Riis AH, Christiansen CF. et al. Clopidogrel use and short-term mortality after peptic ulcer bleeding: a population-based cohort study. Am J Ther 2013; 20 (01) 13-20
623 Ng FH, Wong SY, Chang CM. et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003; 18 (04) 443-449
624 Hsiao FY, Tsai YW, Huang WF. et al. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding. Clin Ther 2009; 31 (09) 2038-2047
625 Wu W, Liu J, Yu H. et al. Antiplatelet therapy with or without PPIs for the secondary prevention of cardiovascular diseases in patients at high risk of upper gastrointestinal bleeding: A systematic review and meta-analysis. Exp Ther Med 2020; 19 (06) 3595-3603
626 Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open 2014; 4 (05) e004587
627 Anglin R, Yuan Y, Moayyedi P. et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109 (06) 811-819
628 Jiang HY, Chen HZ, Hu XJ. et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13 (01) 42-50 e3
629 Targownik LE, Bolton JM, Metge CJ. et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104 (06) 1475-1482
630 Labos C, Dasgupta K, Nedjar H. et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183 (16) 1835-1843
631 Quinn GR, Hellkamp AS, Hankey GJ. et al. Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. J Am Heart Assoc 2018; 7 (15) e008755
632 Swart F, Bianchi G, Lenzi J. et al. Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database. Aging (Albany NY) 2020; 12 (19) 19711-19739
633 de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65 (07) 795-803
634 Iwakiri R, Higuchi K, Kato M. et al. Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Aliment Pharmacol Ther 2014; 40 (07) 780-795
635 Lai KC, Lam SK, Chu KM. et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346 (26) 2033-2038
636 Sugano K, Choi MG, Lin JT. et al. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut 2014; 63 (07) 1061-1068
637 Gaziano JM, Brotons C, Coppolecchia R. et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392: 1036-1046
638 Group ASC, Bowman L, Mafham M. et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379 (16) 1529-1539
639 McNeil JJ, Wolfe R, Woods RL. et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med 2018; 379 (16) 1509-1518
640 Piepoli MF, Hoes AW, Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37 (29) 2315-2381
641 Raber I, McCarthy CP, Vaduganathan M. et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet 2019; 393: 2155-2167
642 Garcia Rodriguez LA, Johansson S, Nagy P. et al. Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care. Thromb Haemost 2014; 111 (01) 131-139
643 Sung JJ, Lau JY, Ching JY. et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152 (01) 1-9
644 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
645 Chan FK, Ching JY, Hung LC. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352 (03) 238-244
646 Lai KC, Chu KM, Hui WM. et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006; 4 (07) 860-865
647 Luo JC, Huang KW, Leu HB. et al. Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer. Aliment Pharmacol Ther 2011; 34 (05) 519-525
648 Chan FK, Kyaw M, Tanigawa T. et al. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin. Gastroenterology 2017; 152 (01) 105-110 e1
649 Ng FH, Wong SY, Lam KF. et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010; 138 (01) 82-88
650 Hsu PI, Lai KH, Liu CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology 2011; 140 (03) 791-798
651 Hsu PI, Wu DC, Tsay FW. et al. Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial. Am J Gastroenterol 2017; 112 (02) 282-289
652 Chan EW, Lau WC, Leung WK. et al. Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study. Gastroenterology 2015; 149 (03) 586-595 e3
653 Hallas J, Dall M, Andries A. et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726
654 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (07) 494-502
655 Hansen ML, Sorensen R, Clausen MT. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170 (16) 1433-1441
656 Schalekamp T, Klungel OH, Souverein PC. et al. Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost 2008; 100 (06) 1076-1083
657 Sorensen R, Hansen ML, Abildstrom SZ. et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967-1974
658 Dewilde WJ, Oirbans T, Verheugt FW. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115
659 Bhatt DL, Cryer BL, Contant CF. et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363 (20) 1909-1917
660 Vaduganathan M, Bhatt DL, Cryer BL. et al. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. J Am Coll Cardiol 2016; 67 (14) 1661-1671
661 Bundhun PK, Teeluck AR, Bhurtu A. et al. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012–2016). BMC Cardiovasc Disord 2017; 17 (01) 3
662 Cardoso RN, Benjo AM, DiNicolantonio JJ. et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart 2015; 2 (01) e000248
663 Chen CH, Yang JC, Uang YS. et al. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos 2012; 33 (05) 278-283
664 Abrignani MG, Gatta L, Gabrielli D. et al. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med 2021; 85: 1-13
665 Choi YJ, Kim N, Jang IJ. et al. Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea. Gut Liver 2017; 11 (04) 504-511
666 Valgimigli M, Bueno H, Byrne RA. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg 2018; 53 (01) 34-78
667 Lip GYH, Collet JP, Haude M. et al. Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI: A Summary of the Joint Consensus Document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Eur Heart J 2018; 39 (31) 2847-2850
668 Knuuti J, Wijns W, Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41 (03) 407-477
669 Fischbach W, Darius H, Gross M. et al. Concomitant use of thrombocyte aggregation inhibitors and proton pump inhibitors (PPIs). Z Gastroenterol 2011; 49 (03) 395-402
670 Furuta T, Sugimoto M, Kodaira C. et al. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis 2017; 43 (03) 333-342
671 Malchow H, Ewe K, Brandes JW. et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86 (02) 249-266
672 Summers RW, Switz DM, Sessions Jr. JT. et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979; 77 (04) 847-869
673 Dickinson JB. Is omeprazole helpful in inflammatory bowel disease?. J Clin Gastroenterol 1994; 18 (04) 317-319
674 Miehsler W, Puspok A, Oberhuber T. et al. Impact of different therapeutic regimens on the outcome of patients with Crohn’s disease of the upper gastrointestinal tract. Inflamm Bowel Dis 2001; 7 (02) 99-105
675 Moon JS, Lee JL, Yu CS. et al. Clinical Characteristics and Postoperative Outcomes of Patients Presenting With Upper Gastrointestinal Tract Crohn Disease. Ann Coloproctol 2020; 36 (04) 243-248
676 Wagtmans MJ, Verspaget HW, Lamers CB. et al. Clinical aspects of Crohn’s disease of the upper gastrointestinal tract: a comparison with distal Crohn’s disease. Am J Gastroenterol 1997; 92 (09) 1467-1471
677 Iijima K, Kanno T, Koike T. et al. Helicobacter pylori-negative, non-steroidal anti-inflammatory drug: negative idiopathic ulcers in Asia. World J Gastroenterol 2014; 20 (03) 706-713
678 Charpignon C, Lesgourgues B, Pariente A. et al. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. Aliment Pharmacol Ther 2013; 38 (08) 946-954
679 Kanno T, Iijima K, Abe Y. et al. A multicenter prospective study on the prevalence of Helicobacter pylori-negative and nonsteroidal anti-inflammatory drugs-negative idiopathic peptic ulcers in Japan. J Gastroenterol Hepatol 2015; 30 (05) 842-848
680 Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009; 30 (08) 791-815
681 Iijima K, Kanno T, Abe Y. et al. Preferential location of idiopathic peptic ulcers. Scand J Gastroenterol 2016; 51 (07) 782-787
682 Freston JW. Review article: role of proton pump inhibitors in non-H. pylori-related ulcers. Aliment Pharmacol Ther 2001; 15 (Suppl. 02) 2-5
683 Dore MP, Soro S, Niolu C. et al. Clinical features and natural history of idiopathic peptic ulcers: a retrospective case-control study. Scand J Gastroenterol 2019; 54 (11) 1315-1321
684 Yoon H, Kim SG, Jung HC. et al. High Recurrence Rate of Idiopathic Peptic Ulcers in Long-Term Follow-up. Gut Liver 2013; 7 (02) 175-181
685 Wong GL, Au KW, Lo AO. et al. Gastroprotective therapy does not improve outcomes of patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Clin Gastroenterol Hepatol 2012; 10 (10) 1124-1129
686 Wong GL, Wong VW, Chan Y. et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009; 137 (02) 525-531
687 Wong GLH, Lau LHS, Ching JYL. et al. Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. Gut 2020; 69 (04) 652-657
688 Chung CS, Chiang TH, Lee YC. A systematic approach for the diagnosis and treatment of idiopathic peptic ulcers. Korean J Intern Med 2015; 30 (05) 559-570
689 Quan C, Talley NJ. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol 2002; 97 (12) 2950-2961
690 Cook DJ, Fuller HD, Guyatt GH. et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994; 330 (06) 377-381
691 Cook DJ, Reeve BK, Guyatt GH. et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996; 275 (04) 308-314
692 Marik PE, Vasu T, Hirani A. et al. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med 2010; 38 (11) 2222-2228
693 Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs 1997; 54 (04) 581-596
694 Krag M, Perner A, Wetterslev J. et al. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med 2015; 41 (05) 833-845
695 Wang Y, Ge L, Ye Z. et al. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: an updated systematic review and network meta-analysis of randomized trials. Intensive Care Med 2020; 46 (11) 1987-2000
696 Zhou X, Fang H, Xu J. et al. Stress ulcer prophylaxis with proton pump inhibitors or histamine 2 receptor antagonists in critically ill adults – a meta-analysis of randomized controlled trials with trial sequential analysis. BMC Gastroenterol 2019; 19 (01) 193
697 Alhazzani W, Alshamsi F, Belley-Cote E. et al. Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials. Intensive Care Med 2018; 44 (01) 1-11
698 Alshamsi F, Belley-Cote E, Cook D. et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care 2016; 20 (01) 120
699 Toews I, George AT, Peter JV. et al. Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units. Cochrane Database Syst Rev 2018; 6: CD008687
700 Krag M, Marker S, Perner A. et al. Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU. N Engl J Med 2018; 379 (23) 2199-2208
701 Australian PIft, New Zealand Intensive Care Society Clinical Trials Group AHSCCSCN, the Irish Critical Care Trials G. et al. Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial. JAMA 2020; 323 (07) 616-626